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6When you stop at the red light
look at the red light
and smile
-Thich Nhat Hanh
To my family
7ABSTRACT
Heart failure is a complex clinical syndrome, most often caused by ischemic,
hypertensive, and valvular heart disease. In this thesis, we studied how
genetic variation contributes to hypertension and acute coronary syndrome,
the most frequent causes of heart failure. We also studied the role of genetic
variation in Takotsubo cardiomyopathy, a disease which still remains poorly
understood and often presents with transient heart failure.
To identify trait-associated genetic variants, we analyzed several
population-based samples of Finns using genetic association tests. Three of
the four publications constituting this thesis are genome-wide association
studies (GWAS).
In the first study, we identified variants near the PRDM6 gene, which
associated  with  both  higher  systolic  blood  pressure  and  a  higher  risk  of
intracranial aneurysms. This result was one of the first to show a shared
genetic background for blood pressure and intracranial aneurysms. Based on
data on the function of PRDM6 and other trait associations in the locus, we
hypothesize  that  the  genetic  variants  at  this  locus  increase  systolic  blood
pressure  and  aneurysm  risk  via  an  effect  on  the  proliferation  of  smooth
muscle cells in the arterial wall.
In  the  second  study,  we  performed  a  GWAS  separately  on  the  two
subtypes of myocardial infarction in acute coronary syndrome, the ST-
segment elevation and non-ST-segment elevation myocardial infarctions
(STEMI  and  NSTEMI).  Genetic  variation  near DRAM2, encoding a protein
participating  in  the  regulation  of  autophagy,  increased  the  risk  of  NSTEMI
with little to no effect on the risk of STEMI. This finding is rather surprising,
given that both infarction types are mostly the result of the same disease
process, namely coronary heart disease.
The third study addressed atrial and B-type natriuretic peptides (ANP and
BNP), which are secreted by cardiomyocytes, both during normal
homeostasis  and  especially  during  acute  heart  failure.  We  identified  a  new
locus  near  the  calcineurin  subunit  gamma  gene PPP3CC, which was
8associated with the ratio of the circulating concentrations of active BNP and
the  N-terminal  fragment  of  the  proBNP  prohormone.  Based  on  the  genetic
results, we also showed that the data specifically supports the blood-
pressure-lowering  effect  of  ANP  in  the  general  population,  and  not  that  of
BNP.
In  the  fourth  study,  we  studied  the  possible  genetic  background  of
Takotsubo cardiomyopathy. The cause of this condition is currently unknown
but a contribution of genetic variation has been suggested in previous
literature. We could not replicate previous genetic findings in the disease to
show that if genetic predisposition exists, it is similar to that of complex
diseases, such as acute coronary syndromes, with small absolute risks
conferred by each of multiple genetic risk variants.
The results of this thesis provide new information on the molecular basis
of the two most common causes of heart failure: hypertension and acute
coronary  syndromes.  They  also  limit  plausible  genetic  models  that  are
compatible with observational data for Takotsubo cardiomyopathy.
9TIIVISTELMÄ
Sydämen vajaatoiminta on oireyhtymä, jonka merkittävimmät syyt ovat
sepelvaltimotauti, verenpainetauti ja läppäviat. Tässä väitöskirjatyössä
tutkittiin perinnöllisen muuntelun yhteyttä sepelvaltimotautiin ja
verenpainetautiin, jotka ovat sydämen vajaatoiminnan tärkeimpiä syitä.
Lisäksi väitöskirjassa selvitettiin Takotsubo-sydänlihastaudin mahdollista
perinnöllistä taustaa. Takotsubo-sydänlihastauti on harvinainen sairaus
johon usein liittyy ohimenevä sydämen vajaatoiminta.
Väitöskirjatyö perustuu geneettisille assosiaatiotesteille suomalaisissa
väestöaineistoissa. Kolme väitöskirjan neljästä osatyöstä on perimänlaajuisia
assosiaatiotutkimuksia (GWAS). Ensimmäisessä osatyössä tunnistimme
geenin PRDM6 lähellä alleeleita, jotka ovat yhteydessä korkeaan
verenpaineeseen ja aivovaltimopullistumien esiintymiseen. Nämä tulokset ja
PRDM6-geenistä aiemmin julkaistut tiedot viittaavat siihen, että PRDM6:n
geeniekspressio valtimonseinän sileissä lihassoluissa saattaa vaikuttaa sekä
valtimoverenpaineeseen että aivovaltimonpullistumariskiin.
Toisessa osatyössä teimme perimänlaajuisen assosiaatiotutkimuksen
kahdesta sydäninfarktityypistä, ST-noususydäninfarktista (STEMI) ja
sydäninfarktista ilman ST-nousua (NSTEMI). Osoitimme, että geneettinen
muuntelu kromosomilla 1 lähellä DRAM2-geeniä altistaa NSTEMI-
infarktityypille, ja että  näiden alleelien vaikutus ST-nousuinfarktiriskiin oli
merkittävästi pienempi. Löydös on yllättävä, sillä molemmat infarktityypit
ovat sepelvaltimotaudin päätetapahtumia.
Kolmannessa osatyössä tutkimme perinnöllistä muuntelua sydämen
erittämien natriureettisten peptidien määrässä ja sen vaikutusta
verenpaineeseen. Eteispeptidi (ANP) ja B-tyypin natriureettinen peptidi
(BNP) ovat sydänlihaksen verenkiertoon erittämiä hormoneita, joiden eritys
lisääntyy sydämen vajaatoiminnan yhteydessä. Suurempaan eteispeptidin
määrään liittyvät geenimuodot olivat yhteydessä matalampaan
valtimoverenpaineeseen ja verenpainetautiriskiin, mutta BNP-määrään
liittyvien geenimuotojen ja verenpaineen välillä ei ollut tilastollisesti
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merkitsevää yhteyttä. Tutkimuksessa tunnistettiin myös harvinainen
suomalaiseen väestöön rikastunut BNP-geenimuoto, joka saattaa häiritä
aminoterminaalisen pro-B-tyypin natriureettisen peptidin (NT-proBNP)
käyttöä sydämen vajaatoiminnan erotusdiagnostiikassa.
Neljännen osatyön perimänlaajuinen assosiaatiotutkimus Takotsubo-
sydänlihastaudista osoitti, että suomalaisessa väestössä ei todennäköisesti
ole tälle taudille voimakkaasti altistavia yleisiä geenimuotoja. Aiemmin
julkaistut tulokset taudin mahdollisesta periytyvyydestä eivät toistuneet
tutkitussa aineistossa. Tulokset eivät tue kirjallisuudessa esitettyä ajatusta
Takotsubo-sydänlihastaudin periytyvyydestä.
Väitöskirjatyön tulokset antavat uutta tietoa sydämen vajaatoiminnan
merkittävimpien syiden mekanismeista ja rajaavat Takotsubo-
sydänlihastaudin mahdollista perinnöllistä taustaa.
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INTRODUCTION
Variation in most human traits is to some degree caused by genetic
differences. The identification and mechanistic understanding of specific
genetic differences in traits will likely eventually lead to a detailed
understanding of how diseases, such as coronary heart disease, hypertension,
or Alzheimer's disease, develop. This understanding, in turn, can be used to
develop efficient preventive measures and treatments.
Technological and scientific advances in the 21st century have resulted in
methods enabling large-scale investigation of human genetic variation. This
thesis comprises four studies applying these methods to identify genetic
differences in traits relevant to the onset of heart failure. Rather than an
independent  disease,  heart  failure  is  a  syndrome  that  may  be  caused  by
various diseases. Most notably, coronary artery disease and hypertensive
heart disease are both the main causes of heart failure and also among the
leading causes of death world-wide [1,2]. In the vast majority of cases, heart
failure is a multifactorial or complex trait, caused by many genetic and
environmental factors acting in concert. [3,4]
The studies presented here are based on data from the Finnish
population. The characteristics of genetic variation in Finns have favoured
genetic investigation, particularly genetic research in monogenic disease
focusing on pedigrees [5]. Studies of common complex disease, on the other
hand, depend on large, well-characterised study samples. Population-based
cohorts  of  Finns,  such  as  the  National  FINRISK  Study  cohorts,  are  thus
central  to  the  work  presented  in  this  thesis.  However,  results  from  one
population are not limited to that population alone. Although differences
between human populations do exist, they are rather small and results from
one population are mostly applicable to others as well [6,7].
REVIEW OF THE LITERATURE
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1 REVIEW OF THE LITERATURE
1.1 HEREDITY
Living  beings  pass  on  some  of  their  traits  to  their  offspring.  This
transmission of traits from one generation to the next, called heredity or
inheritance,  is  one  of  the  defining  features  of  life.  The  scientific  study  of
inheritance was pioneered in the 19th century by Gregor Mendel, an
Augustinian monk. Working on the common pea plant, he discovered
fundamental mathematical rules describing the distribution of traits, such as
flower color in the offspring when crossing different pea plants. Although he
was certainly not the first person to study heredity, Gregor Mendel is
regarded as the founder of the modern scientific study of inheritance,
nowadays known as genetics.
The basic unit of hereditary information is the gene. Genes determine the
molecular  structure  and  function  of  cells.  On  the  molecular  level,  genes  of
cellular organisms are composed of deoxyribonucleic acid or DNA [8].
Solving the structure of DNA in 1953 and, subsequently, deciphering how
genetic information is stored in DNA, transcribed into RNA, and translated
into proteins are among the greatest scientific achievements ever made [9-
11]. The understanding of how genes are physically encoded into DNA
provides us with a mechanistic explanation of how traits can pass from one
generation to the next.
Since Mendel's days, great effort has been made in trying to understand
how, exactly, genes influence different traits in various organisms. This is not
a trivial task. After all, genes are somehow able to guide the development of
living beings, arguably the most complex entities known to science.
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1.2 DNA
1.2.1 STRUCTURE OF DNA
DNA is composed of nucleotides. Linked together by covalent bonds,
nucleotides contain a nitrogenous base, either adenoside (A), thymine (T),
cytosine (C) or guanine (G), which together form the letters of the DNA code.
Two chains or strands of DNA are bound together via hydrogen bonds so that
C always binds to G on the opposite strand and A always binds to T. When
the two strands of  a  DNA molecule are bound by base-pairing,  they curl  up
together  as  though  wrapping  around  a  common  axis,  forming  the  iconic
double helical shape of DNA. [12]
1.2.2 MUTATION AND RECOMBINATION
Mutations,  errors  in  maintaining  DNA's  nucleotide  sequence,  give  rise  to
genetic variation between individuals of a given species. They are also the
reason  why  the  genomes  of  different  species  are  dissimilar.  Mutations
occurring in the germline cells can pass from parents to their offspring, while
mutations altering the genetic sequence in somatic cells cannot.
Mutations produce new alleles, alternative genetic sequences in a given
genomic location or locus. Point mutations are the simplest type of
mutations, changing one nucleotide into another. Deletions and insertions
either remove or insert one or more nucleotides. Duplication and
amplification are special cases of insertions, increasing the number of copies
of a given genetic sequence. Translocations delete a stretch of DNA but insert
it to a new location in the genome. Inversions flip a sequence of DNA around,
otherwise maintaining its position and sequence in the genome.
Variant alleles, the results of mutations, are divided into single-nucleotide
polymorphisms (SNPs) produced by point mutations, indels originating from
insertions and deletions, and more complex alleles such as translocations
and inversions [12]. Some of the complex alleles are often grouped together
under the terms copy number variation (CNV) and structural variation (SV)
[6,13].
REVIEW OF THE LITERATURE
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During meiosis, the homologous chromosomes of each chromosome pair
align  against  each  other  and  physically  exchange  stretches  of  DNA.  This
recombination of chromosomes shuffles alleles between homologous
chromosomes, producing chromosomes with new combinations of alleles.
Chromosomes then segregate randomly so that each mature sex cell receives
only one copy of each chromosome. Errors in this process may occur, causing
aneuploidies, where the number of chromosomes in the cell is abnormal.
Mutation and recombination are the driving forces creating genetic diversity
in  populations,  producing  new  alleles  and  creating  new  combinations  of
alleles.
1.3 ALLELES IN POPULATIONS
1.3.1 ALLELE AND GENOTYPE FREQUENCIES
The distribution of alleles in populations are described by two central
metrics, their allele and genotype frequencies. The frequency of an allele is its
relative  frequency  in  a  population  or  a  sample,  i.e.  the  proportion  of
individual chromosomes carrying said allele. In biallelic loci, the rarer allele
is referred to as the minor allele. The frequency of the more common allele is
thus 1 - the minor allele's frequency (MAF).
Genotype frequencies, or the proportion of genotypes in a sample or
population, depend on allele frequecies. The Hardy-Weinberg principle
shows that, in the absence of evolutionary forces, genotype frequencies
depend only on allele frequency. For a biallelic locus with alleles p and q, the
genotype frequencies are given by
1 = ݌ଶ + 2݌ݍ + ݍଶ
where p2, 2pq, and q2 are the genotype frequencies for the pp homozygotes,
the heterozygotes, and the qq homozygotes, respectively [14].
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1.3.2 LINKAGE DISEQUILIBRIUM
When a mutation occurs on a given chromosome, the resulting mutant allele
is physically linked to all other alleles already present on said chromosome at
other  loci.  Until  the  physical  link  between  the  alleles  is  broken  by
recombination, the alleles are inherited together as a haplotype, introducing
correlation between the alleles. As the probability of a recombination event
between two chromosomal positions is proportional to the distance between
the positions, alleles close to each other are more strongly correlated than
alleles separated by longer distances. The distribution of recombination
events is not uniform, however, and some genomic regions are much more
prone to recombination events ("recombination hotspots") than others [15].
Correlation or non-independence between alleles in different genomic loci
is collectively denominated linkage disequilibrium (LD). When two alleles
are in linkage equilibrium, the population frequency of chromosomes
carrying both alleles is the product of the alleles' frequencies, as given by the
definition of independent events in probability theory. Formally, given a
locus with alleles A and a with frequencies pA and qa, and a second locus with
alleles B and b with frequencies pB and qb, the frequency PAB of chromosomes
carrying alleles A and B is  given  by  the  alleles'  frequencies  and  the  linkage
disequilibrium parameter D [16]:
஺ܲ஻ = ݌஺݌஻ + ܦ
The linkage disequilibrium parameter D depends on allele frequencies,
making  it  somewhat  difficult  to  compare  values  of D for  different  pairs  of
alleles. A more easily interpreted value D' is commonly used, expressing D as
the proportion of its greatest (if positive) or smallest (if negative) possible
value given the frequencies of the two alleles [17]. Often, the sign is omitted
and only the absolute value is reported. This ensures that D' always falls
within [-1, 1] or [0, 1], making it more meaningful and easy to compare:
REVIEW OF THE LITERATURE
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ܦԢ = ஽஽ಾಲ೉ = ቐ
஽
௠௜௡{௤ೌ௣ಳ, ௣ಲ௤್}
, ܦ ൒ 0
஽
௠௜௡{௤ೌ௤್, ௣ಲ௣ಳ}
, ܦ < 0
It is often natural to interpret linkage disequilibrium in terms of how well
knowing  the  genotypes  of  one  of  the  alleles  can  predict  the  other. D' partly
answers this, as it directly describes how often the rarest of the alleles at the
two loci  is  met  on  the  same chromosome with  the  more  common alleles  in
the other locus. If the absolute value of D' equals one, the rarest of the four
alleles perfectly predicts the genotypes at the other locus, being either always
(D' = 1) or never (D' = -1) on the same chromosome with one of the two more
common alleles at the other locus. The opposite, however, does not apply, as
D' does  not  readily  describe  how well  the  more  common allele  predicts  the
rarer allele. The squared correlation coefficient r2 overcomes this asymmetry
and provides a general measure of correlation between two alleles [18]:
ݎଶ = ܦ
ଶ
݌஺ݍ௔݌஻ݍ௕
Compared to D', the squared correlation coefficient r2 captures another
side  of  the  relationship  between  two  alleles  at  two  loci.  This  is  particularly
evident in how differences in allele frequencies affect the two measures. A
large difference in allele frequencies guarantees a small value of r2, while D'
is independent of allele frequency differences. D' is perhaps biologically more
meaningful, as a new mutant allele has D' =  1  with  all  other  alleles  on  the
chromosome until recombination breaks the linkage. The squared correlation
coefficient r2 is a more abstract statistical measure of linkage disequilibrium.
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1.4 THE HUMAN GENOME
1.4.1 STRUCTURE
Due  to  genetic  variation,  the  genomes  of  any  two  individuals  are  different,
barring the special case of clones such as monozygotic twins. Thus, the
human  genome  as  a  concept  is  an  abstract  idea,  which  does  not  exactly
correspond to the genome of any specific human. In practice, it is used as a
shorthand for "a typical human genome" or in reference to a specific model
of the genomes of humans1.
Most humans inherit one copy of each nuclear chromosome from both
parents, making humans a diploid species. Oocytes and sperm cells each
carry a haploid human genome, containing approximately 3.2 billion base
pairs of DNA distributed into 23 nuclear chromosomes (Figure 1, Table 1)
[19,20]. Chromosome 1, the largest human chromosome, contains
approximately  five  times  as  much  DNA  as  the  smallest,  chromosome  21.
Some chromosomes contain few genes relative to their physical size, while
e.g. the diminutive chromosome 19 packs approximately 25 genes per million
base pairs (Mbp), four times the genomic average of 6.5 genes per Mbp [21].
In  addition  to  the  nuclear  chromosomes,  oocytes  and  sperm  cells  also
carry mitochondria, which have multiple copies of their own small
chromosome. Oocytes contain approximately 106 mitochondria, whereas the
sperm cells hold few mitochondria, which are destroyed when the sperm
enters the oocyte [22]. Thus, in contrast to the nuclear chromosomes, the
multiple  copies  of  the  mitochondrial  chromosome  are  inherited  from  the
mother only.
As the structure and contents of the human genome are the result of its
evolutionary history, sequence conservation can be used to detect
functionally constrained elements in the genome. Approximately 5.5% of the
entire human genome is under purifying natural selection, while the
remaining 94.5% appears to evolve neutrally unaffected by natural selection
[23]. Although sequence conservation during evolution is not a perfect
measure of biological function, this strongly suggests that the bulk of the
1 E.g. the Genome Reference Consortium human reference genome assembly GRCh38.p11
REVIEW OF THE LITERATURE
24
DNA  sequence  in  the  human  genome  carries  little  biologically  important
information.
Roughly 50% of the human genome consists of repetitive DNA sequences
which  contain  few genes,  such  as  the  tandemly  repeat  sequences  present  at
centromeres and telomeres [19]. Most of the repetitive elements of the
genome  are  formed  by  inactive  transposons.  Hundreds  of  thousands  of
inactive transposons are found throughout the nuclear genome, together
comprising  a  striking  44%  of  its  total  size.  Compared  to  the  number  of
inactive transposons, there are few active transposons, producing an average
of 0.1 to 0.01 new insertions per live birth. [24] Furthermore, little if any of
the repetitive DNA in the human genome has been under purifying natural
selection [23]. The repetitive DNA sequences in the human genome are thus
mostly inactive transposable elements and appear to serve no sequence-
specific purpose.
The conserved 5.5% of the human genome contains genes and regulatory
elements. Proteins are the main drivers of biochemical activity in cells, with
the notable exception of protein synthesis itself, but the exons of classical
protein-coding  genes  occupy  only  1.5%  of  the  human  genome.  Most  of  the
functional elements of the human genome must, therefore, serve a regulatory
function,  making sure the right amount of proteins are expressed in the right
cells at the right time.
Figure 1. The human genome. The sizes of the human chromosomes are shown in
base pairs (top row) as well as relative to the number of protein coding genes on each
chromosome (bottom row). The physical size of chromosomes only partially correlates
with the amount of genes they contain, due to the uneven genomic distribution of a vast
amount of mostly repetitive DNA encoding no genes. Figure based on the GRCh38p11
reference genome and the GENCODE v27 gene annotation set [20,21]. N.B.: The
mitochondrial chromosome is too small to be visible at this scale.
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Table 1. The human genome.
Chr
Size (bp)*
Protein-coding
genes†
Other
genes†
Genes per Mbp
(protein-coding / other)
total 3,088,269,832 20,036 23,544 6.49 / 7.62
1 248,956,422 2,040 1,988 8.19 / 7.99
2 242,193,529 1,301 1,652 5.37 / 6.82
3 198,295,559 1,072 1,184 5.41 / 5.97
4 190,214,555 747 1,024 3.93 / 5.38
5 181,538,259 882 1,278 4.86 / 7.04
6 170,805,979 1,035 1,020 6.06 / 5.97
7 159,345,973 902 1,091 5.66 / 6.85
8 145,138,636 668 1,083 4.6 / 7.46
9 138,394,717 769 808 5.56 / 5.84
10 133,797,422 728 909 5.44 / 6.79
11 135,086,622 1,279 1,136 9.47 / 8.41
12 133,275,309 1,033 1,304 7.75 / 9.78
13 114,364,328 323 613 2.82 / 5.36
14 107,043,718 701 988 6.55 / 9.23
15 101,991,189 606 1,037 5.94 / 10.17
16 90,338,345 864 1,175 9.56 / 13.01
17 83,257,441 1,185 1,296 14.23 / 15.57
18 80,373,285 268 659 3.33 / 8.2
19 58,617,616 1,468 968 25.04 / 16.51
20 64,444,167 540 602 8.38 / 9.34
21 46,709,983 235 419 5.03 / 8.97
22 50,818,468 487 524 9.58 / 10.31
X 156,040,895 840 654 5.38 / 4.19
Y 57,227,415 63 108 1.1 / 1.89
M 16,569‡ 13 24 784.6 / 1448.49
* GRCh38.p11 reference assembly [20]
† GENCODE v27 comprehensive gene annotation set [21]
‡ The revised Cambridge reference sequence of the human mitochondrial DNA (NCBI RefSeq NC_012920.1)
1.4.2 GENES
Genes are the basic units of genetic information. The precise meaning of the
term  is  frequently  refined  as  genetics  as  a  science  progresses  and  our
understanding of how genes work improves. According to a modern
definition, an individual gene "is a union of genomic sequences encoding a
coherent set of potentially overlapping functional products" [25]. In
practice, the functional products of genes are RNA transcripts. Genes are
thus genomic sequences which are transcribed into a related set of functional
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RNA molecules. If at least one of the RNA molecules encoded by a gene is a
messenger RNA molecule, translated by ribosomes into a protein, the gene is
referred to as a protein coding gene, otherwise as a non-coding gene.
There  are  approximately  20,000 protein  coding  genes  and,  according  to
some estimates, over 23,000 non-coding genes in the human genome (Table
1)  [21].  While  there  is  a  broad  consensus  of  the  identity  and  amount  of
human protein coding genes, the number of non-coding genes is much more
uncertain. The v27 comprehensive gene annotation set produced by the
GENCODE consortium annotates 23,544 non-coding genes, but the NCBI
Homo sapiens annotation release 108 contains only 17,835 [25-27]. The wide
discrepancy in these estimates reflects the fact that protein coding genes are
much more studied and better understood than non-coding genes.
Few mammalian protein coding genes encode a single transcript. Instead,
most are transcribed into multiple alternative RNA isoforms, some of which
may correspond to different protein isoforms and some which are never
translated. As a typical example, consider the human gene DRAM2, shown in
Figure  2  (panels  A-C).  The  promoter  region  and  transcription  start  sites
(TSS's) of DRAM2 overlap with those of the adjacent gene CEPT1 (Panel D).
DRAM2 encodes two well-annotated mRNA's, which have slighty different
transcription TSS's. The two mRNA's thus have different first exons, which
contain the 5' untranslated regions (UTR's, panel A). The DRAM2 gene also
produces a transcript with a very different open reading frame (ORF), which
might  be  translated  into  a  protein  but,  according  to  current  annotation,  is
instead eliminated via nonsense-mediated degradation (Panel B). The exons
of DRAM2 are much more conserved than its introns and appear as spikes on
a graph of sequence conservation (Panel F). As most genes, DRAM2
produces a significant number of processed noncoding transcripts, which do
not contain an ORF (Panel C). The biological significance of these, if any, is
currently unclear. [21]
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Figure 2 The gene DRAM2 and its genomic environment. Transcripts are shown as
annotated in GENCODE v19, oriented so that the promoter and 5' side of DRAM2 are on
the right [21]. (A) Protein-coding DRAM2 transcripts. (B) A DRAM2 transcript degraded via
nonsense-mediated decay. (C) Non-coding DRAM2 transcripts. (D) Transcripts from the
adjacent gene CEPT1, which partially overlap DRAM2. (E) Transcription factor binding
sites detected in multiple cell types by the Encyclopedia of DNA Elements (ENCODE)
consortium [28]. (F) Sequence conservation based on sequence alignments of 100
vertebrate genomes (G) Repeating DNA elements by RepeatMasker. Tracks E to G
extracted from the UCSC Genome Browser on 22.9.2017 [29].
1.4.3 GENE REGULATION
Differences in cell types in multicellular organisms are caused by differential
gene  expression.  Thus,  an  important  portion  of  the  human  genome  is
dedicated to regulating the expression of genes. Some of its mechanisms are
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genetic or direcly dependent on specific DNA sequences, but some are
epigenetic  or  unrelated  to  the  DNA  sequence  itself  [30].  In  cells,  DNA  is
tightly packed around proteins, most importantly histones, forming
chromatin, which is inaccessible to the machinery responsible for
transcription. The organization and epigenetic control of chromatin
structure, e.g. via DNA methylation and histone modification, play an
important role in controlling which genes are actively transcribed. [31]
Two classes of regulatory sequences, promoters and enchancers, are
central to driving the expression of eukaryotic genes and the genetic or
sequence-specific control gene expression. Promoters ensure that
transcription is initiated at the correct position. They contain the core
promoter where the basic molecular machinery responsible for synthesising
RNA is assembled and which may also bind other transcription factors
affecting the level of expression. [12] Enhancers, on the other hand, are distal
elements which bind transcription factors, interact with the promoter, and
increase  gene  expression,  mostly  irrespective  to  the  exact  position  of  the
enhancer relative to the target promoter [32].
Many systematic efforts have cataloged and characterized regulatory DNA
and epigenetic landscapes in diverse cells. They include strategies such as
screens of transcription factor binding sites, histone modifications, and DNA
methylation, as well as screens of chromatin accessibility (Panel E, Figure 2).
[33,34] Although advances have been made in identifying e.g. enhancer
elements, comprehensive understanding of gene regulation still requires
significant  progress  [35].  The  function  of  distal  regulatory  elements  in  the
human genome is particularly poorly understood.
1.5 HUMAN GENETIC VARIATION
SNPs are numerically by far the largest class of genetic variants in humans
with  millions  of  SNPs  identified  to  date  (on  10.2.2018  the  NCBI  dbSNP
database includes 325.7 million reference SNP ID numbers) [36]. Humans
carry a SNP allele at an average of 1,500,000 sites per individual. [6] Due to
their high number and relatively easy accessibility to different laboratory
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methods, SNPs have gained a prominent position in human genetic research,
where the term SNP is commonly used as a synonym of small or short genetic
variants in general. The other variant classes tend to receive less attention,
although CNVs,  for  example,  encompass  a  larger  proportion  of  the  genome
than SNPs [13].
The overwhelming majority of variant alleles constituting human genetic
variation, the genetic differences between humans, are not new mutations. A
typical human genome differs from the human reference genome at 4.1
million to 5.0 million sites, but carries, on average, less than 80 de novo
mutations [6,37]. Human genetic variation is therefore, by and large, related
to alleles inherited from previous generations. Thus, the characteristics of
human genetic variation are mostly the result of human population history
and forces acting on historical timescales, such as migrations and population
growth.  For  example,  in  a  sample  of  African  Americans,  the  average  age  of
variant alleles in protein coding genes was estimated to be 47,600 years [38].
1.5.1 GLOBAL POPULATION HISTORY AND GENETIC VARIATION
Both paleontological and genetic evidence place the lower limit for the age of
Homo sapiens as a species to roughly 300,000 years [39-41]. According to
current understanding, anatomically modern humans spread out of Africa to
inhabit the rest of the world some 100,000 to 50,000 years ago [42,43]. The
number of individuals whose descendants first populated regions outside
Africa was quite small, corresponding to an effective population size of
approximately 1,000 to 5,000 [44,45]. With global population size
increasing, new territories were populated during the following millennia by
select groups of people, giving rise to local subpopulations [46,47].
When  humans  were  living  only  in  Africa,  there  were  on  the  order  of
100,000 to 500,000 people in the world [45,48]. Following the colonization
of the world outside Africa, global population size increased notably, and the
growth rate accelerated roughly five-fold some 10,000 years ago, coinciding
with the invention and adoption of agriculture [49]. Growth then stayed
roughly constant until the population explosion brought by the industrial
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revolution  in  the  19th  century,  when  the  world's  population  grew  from  1
billion to more than 7 billion in just two centuries [50,51].
The way the globe was populated left important marks on the genetic
variation of present-day humans. The entire process can be roughly modeled
as  a  series  of  founder  effects  originating  in  Africa,  with  some  migration
between the resulting populations [46]. A founder effect, in which a relatively
small number of individuals or founders give rise to a new population, is
characterized  by  a  loss  of  genetic  diversity  and  the  outsize  frequency  of  the
alleles carried by the founders in the subsequent generations. Furthermore,
as rare alleles are less likely to be carried by the founders and more likely to
be  lost  due  to  genetic  drift  in  small  populations,  the  rarest  alleles  are  most
likely lost during and following a founding event, when the population size is
not large. [52] Non-African populations have thus inherited a subset of the
genetic variation found in Africa, so that each successive founding event
came with a corresponding loss of genetic diversity with rarer alleles lost
more often than more common ones. [44,46]
Contrary to the disappearance of rare alleles in founding events,
population growth leads to an accumulation of rare alleles. Importantly,
much  of  the  growth  of  human  populations  has  occurred  recently,  after  the
colonization  of  the  world  outside  Africa.  This  recent  population  growth  has
thus increased the number of rare alleles in human populations but, as the
growth occurred after the populations had diverged, many of these alleles are
not  shared  between  the  populations.  [6,53]  Together,  these  two  forces,  the
ancient serial founding effects out of Africa and the relatively recent
explosive population growth, have created the two defining features of global
genetic  variation  of  humans:  First,  alleles  which  are  common  in  any  given
non-African population are very likely old and common in others as well
(Figure 3) [6,54]. Second, there is a multitude of younger rare alleles, many
of which are population-specific (Figure 3; Figure 4) [53].
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Figure 4 Allele frequency distribution and genetic variation. The gray bars show the
proportion of all variable sites according to their minor allele frequencies. The black bars
show the same proportion weighted by the number of non-reference alleles carried across
the study participants. Data from whole-genome sequencing data from the 1000 Genomes
Project Phase 3 variant calls on chromosome 1 [6].
1.5.2 POPULATION HISTORY OF FINNS AND GENETIC VARIATION IN
FINLAND
The  colonization  of  Finland  was  one  end  of  the  serial  founder  events
originating out of Africa. Situated at the northern edge of the habitable
world, Finland was covered by ice until the end of the last glacial period some
10,000 years ago. As the ice sheet retreated, nomadic hunter-gatherers
explored  the  lands  and  were  the  only  inhabitants  for  millennia.  [55]  It  is
thought  that  most  of  what  would  later  be  called  the  ancestors  of  modern
Finns  arrived  much  later,  some  4,000  years  ago,  with  another  significant
migration  into  Finland  approximately  2,000  years  ago  [5].  The  number  of
these founders has been estimated to be quite small. For most of the time,
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since the arrival of the first migrants to Finland, they inhabited only the
southernmost coastal area of the country. [5,56]
The population size of Finland stayed small for centuries after the
migration waves 4,000 and 2,000 years ago. In the 12th century, there were
only  an  estimated  50,000  Finns  [5].  The  small  number  of  founders,  the
resulting  small  population  size  of  Finland,  and  the  very  slow  growth  in
population size lasting for centuries created a genetic bottleneck. This lead to
a substantial loss of genetic variation in Finns relative to its neighboring
countries  [56].  Many  rare  alleles  were  entirely  lost,  leading  to  a  general
deficit  of  rare  alleles  in  Finns  relative  to  most  other  Europeans  [57].
Conversely, many of the rare alleles which survived the bottleneck increased
in frequency becoming much more common. As a result, there are
approximately at least 30,000 alleles which are relatively common in Finns
(MAF>5%), but rare (MAF<0.5%) in other populations, including non-
Finnish Europeans, although this estimate is limited by the small number of
Finns surveyed [6].
In the 16th century the population of Finland started to grow, and regions
outside the coastal areas started to be more extensively populated. Isolation
by  geographic  distance  was,  however,  strong  and  with  limited  internal
migration. The treaty of Nöteborg (Pähkinäsaaren rauha) in 1323 established
the first official border in Finland, then a part of the Swedish kingdom. This
appears to have created a permanent impediment of internal migration and
left an important imprint in the Finnish population with marked differences
between  Finns  living  in  the  south  and  west  as  compared  to  those  living  in
eastern or northern Finland. [58-60]
1.6 GENETIC VARIATION IN TRAITS
1.6.1 HERITABILITY
In  attempting  to  understand  the  causes  of  variability  in  a  trait,  such  as
susceptibility to a disease, it is helpful to be able to divide the variability into
variability caused by genetic and non-genetic causes. The concept of
heritability  formalizes  this  division  and  can  be  used  to  quantify  the
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proportion of total variability that can be accounted for by genetic factors.
[61,62] The total phenotypic variance in a trait can be divided into variance
attributable to genetic and non-genetic or environmental factors as
ܸܲ = ܸܩ + ܸܧ
where VP, VG, and VE denote the total, genetic, and environmental
variances, respectively. The genetic variance can be further divided into
additive, dominance, and interaction effects VA, VD, and VI:
ܸܩ = ܸܣ + ܸܦ + ܸܫ
Given these definitions, the proportion of phenotypic variability caused by
genetic effects or the broad sense heritability of the trait H2 is given by
ܪଶ = ܸீ
௉ܸ
while h2, defined as
݄ଶ = ஺ܸ
௉ܸ
and known as the narrow sense heritability, is the proportion attributable to
additive genetic effects. [63]
Heritabilities have been estimated for hundreds of human traits using
various different methodologies. [63,64] According to a meta-analysis of
2,748 publications estimating heritabilites using the classical twin study
design, for almost all traits the narrow sense heritability is nearly equal to the
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broad sense heritability with a mean value of h2=0.488 across the 17,804
traits included in the analysis [64]. Thus, as a rule of thumb, roughly half of
the  variance  of  any  given  human  trait  may  be  expected  to  be  caused  by
genetic variation.
1.6.2 PENETRANCE AND EFFECT SIZE
The phenotypic consequences of genetic variation range from non-existent to
lethal physiological defects. The vast majority of variant alleles in humans
have no detectable phenotypic effects. Most of those that affect the
phenotype are neutral in terms of natural selection [65]. Furthermore, many
of those alleles that may change the phenotype often do so only under certain
circumstances [66].
The probability that an individual carrying a given genotype will express a
specific qualitative phenotypic effect is called the genotype's penetrance [67].
Penetrance is not a function of only the biological properties of a given allele.
Instead, genetic and environmental backgrounds are important factors
defining the penetrance of the genotypes of many alleles. Importantly, the
penetrances are at least in theory modifiable: A successful treatment of a
genetic disease reduces the disease allele's penetrance. Likewise, a
population-based intervention targeting a disease's environmental risk
factors may positively affect the penetrances of the alleles contributing to the
disease's prevalence.
For quantitative traits, the effect of an allele needs to be expressed relative
to an arbitrarily selected reference genotype. The effect can then be stated in
terms of the mean phenotypic difference between the genotypes, such as the
mean difference in blood pressure between heterozygotes and reference
homozygotes. For quantitative traits, effect sizes are often expressed relative
to the sample standard deviation, which enables comparisons across
different samples and phenotypes measured in different units such as body
mass and height.
Analogous to quantitative traits, the effects of alleles contributing to
qualitative traits can also be expressed relative to a reference genotype. For
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disease traits, two related measures, the relative risk (RR) and the odds ratio
(OR) are often used. Given a disease D, a genotype i and a reference genotype
r, they are defined as follows [67]:
ܴܴ௜ =
ܲ(ܦ|݅)
ܲ(ܦ|ݎ)
ܱܴ௜ =
ܲ(ܦ|݅) / ൫1 െ ܲ(ܦ|݅)൯
ܲ(ܦ|ݎ) / ൫1 െ ܲ(ܦ|ݎ)൯
The  relative  risk  RR  is  thus  easily  understood  as  the  ratio  of  the
penetrances of a genotype and a reference genotype. While there is no
similarly intuitive interpretation for the odds ratio, it has useful statistical
qualities making it often used in practice. Notably, the odds ratio is directly
related  to  the  regression  coefficient  of  an  independent  variable  in  a  logistic
regression model [68].
1.6.3 MONOGENIC TRAITS AND DISEASES
Some diseases or traits are caused by a single disease allele. These monogenic
diseases are often rare and severe. [12,69,70] Alleles causing monogenic
diseases have typically high penetrance and, if the diseases are severe, the
frequency of the disease alleles is low as a result of purifying selection against
the alleles [69-71].
The inheritance of many monogenic diseases displays dominance, i.e. the
phenotype or the penetrance of the heterozygous genotype is very close to
one of the homozygotes, rather than being at an intermediate point between
the two [12,70]. In the case of recessive monogenic diseases, the
heterozygotes carrying only one copy of the disease allele do not have the
disease. Conversely, in dominant recessive diseases, the heterozygotes are
affected with the disease. These modes of inheritance and their unique
segregation patterns in pedigrees were described by Mendel based on his
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experiments with plants. Because of this, monogenic diseases are often also
called Mendelian diseases.
Although an important number of monogenic diseases remain poorly
understood, Mendelian disease genetics has been very successful in
identifying specific disease alleles and genes [69]. A notable example of this
success is the identification of disease alleles responsible for a group of
monogenic diseases, which are much more common in Finland than
elsewhere in the world, constituting what was named as the Finnish disease
heritage by the pioneering Finnish geneticist Reijo Norio [5].
1.6.4 COMPLEX TRAITS AND DISEASES
Many diseases and phenotypes are determined by the alleles of many genes
together with environmental factors. These complex or multifactorial traits
include most familiar phenotypes and diseases, such as height, body mass,
blood pressure, and coronary artery disease. Complex diseases, as opposed to
monogenic diseases, are typically common in the population, have a late
disease onset with a strong component of environmental or life style factors
affecting the disease risk. [12]
At the turn of the 21st century, some scientists engaged in a debate
regarding the genetic structure or architecture of common diseases. In
theory, many different genetic models are compatible with the observed
characteristics of late-onset common diseases, such as coronary artery
disease.  The  central  point  of  the  debate  concerned  the  frequency  of  the
disease risk alleles. They could be quite common in the population, in which
case they necessarily would have, at most, modest penetrances to be
compatible with the observed prevalences of said diseases. Conversely, there
could be a multitude of rare disease alleles, even if the diseases themselves
were relatively common. If the disease alleles were rare, the observed disease
prevalences would be compatible with many possible penetrance
distributions of the rare alleles. [72,73]
A specific study design, the genome-wide association study (GWAS), was
suggested based on the idea of the existence of common disease risk alleles.
[73,74] This study design has since been used to investigate a wide variety of
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complex  phenotypes,  including  common  complex  diseases.  As  a  partial
confirmation of the "common disease, common variant" hypothesis, a
general theme for the various phenotypes studied is that complex traits have
a  high  number  of  common contributing  alleles.  However,  the  effect  sizes  of
these alleles are much smaller than anticipated, with the heterozygous odds
ratios  typically  ranging  from  1.1  to  1.4,  and  their  number  has  also  been
greater than expected by many. [75,76]
1.7 GENETIC MAPPING OF TRAITS
Identifying genes and genetic variants affecting the occurrence of traits and
diseases has both intrinsic value as a way to advance our biological
understanding and instrumental value as a means to develop e.g. diagnostics,
therapeutics, or other interventions for disease. Genetic mapping,or
determining the locations of genes or alleles correlated with traits, can be
roughly divided into studies where the genetic makeup of an organism or
cells is artificially manipulated and studies investigating the phenotypic
correlations of naturally occurring genetic variation.
Studies of humans are, for obvious reasons, limited to studying either
naturally occurring genetic variation or cell models. Many traits and diseases,
however, are not easily reproduced using cellular models. Furthermore,
developing a useful cellular model typically requires some understanding of
the relevant disease processes, which is often lacking. Studying the effects of
naturally occurring genetic variation is thus the primary means of genetic
mapping in humans.
1.7.1 THE P-VALUE AND STATISTICAL POWER
The success of a genetic association study depends on its ability to declare
true associations as statistically significant. This concept, known as statistical
power, is defined in relation to the null hypothesis H0. In the context of
genetics, H0 includes  the  assumption  of  no  dependence  or  association
between the genotypes and the trait under study. H0 is  used  to  justify  a
statistical model of the data, which relates the observations to a random
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variable with a known distribution. The value of the random variable
corresponding to the observations, known as the test statistic, is compared to
its distribution to calculate the probability of the test statistic being at least as
extreme as its value calculated from the data. This probability is known as
the test's P-value. If the P-value is smaller than some value Į,  the  null
hypothesis is rejected and the test is declared statistically significant. Setting
the value of Į therefore defines how often it is acceptable to declare tests
statistically significant when the null hypothesis is true. Scientific literature
commonly accepts the value Į=0.05.
Depending on whether H0 is true or false, two types of correct statistical
decisions and two types of incorrect decisions can be made. Type 1 error, or
false positive results, rejects H0 when it is true. Type 2 error, or false negative
results,  do  not  reject  H0 when it is not true. True positive results reject H0
when it is not true, and true negative results do not reject H0 when it is not
true (Table 2).
The power of a statistical test is the probability of getting a P-value
smaller than Į when the null hypothesis is not true. The power of a study is
often estimated to assess whether a study design is able to produce
meaningful results. Various parameters need to be determined (e.g. effect
size and LD between the causal variant and the marker), after which desired
statistical models can be used to produce power estimates.
Statistical hypothesis testing using P-value cutoffs has been criticized, as
it is somewhat arbitrary and often misused or misunderstood. Some have
advocated abandoning it entirely, while others suggest changing the accepted
cutoffs to more stringent values. [77,78] However, at least for the time being,
most biomedical journals and reviewers of scientific papers in practice
require the use of P-values.
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Table 2. Statistical testing.
Decision
Reality
No association Association
Reject H0
False positive
(Type 1 error) True positive
Do not reject H0 True negative
False negative
(Type 2 error)
1.7.2 GENETIC LINKAGE AND ASSOCIATION
Establishing a connection between an allele and a trait eventually boils down
to studying their co-occurrence. Two general types of tests have been used in
human genetics: tests of linkage and tests of association. Genetic linkage
studies investigate the co-occurrence of transmission of alleles and the
phenotype from parents to their offspring in pedigrees. As the studies
constituting this thesis did not employ tests of genetic linkage, this class of
tests is not discussed further here. Genetic association studies, on the other
hand, compare the frequencies of alleles between classes of individuals (e.g.
affected vs. unaffected) or trait values between genotype classes (e.g. the
height of homozygotes vs. heterozygotes). [67] To explicitly denote that
genetic variants assayed in typical genetic mapping studies are often not
expected  to  be  the  actual  causal  variants,  they  are  called  marker  loci  or
genetic markers.
1.7.3 GENOME-WIDE ASSOCIATION STUDIES
The first genetic association studies were strongly hampered by the poor
technological capacity to determine the genotypes of genetic variants. Until
roughly 2005, it was only feasible to asses the genotypes at a few variant
positions. Scientists thus tried to guess which genes might have something to
do  with  their  trait  of  interest  and  selected  the  few genetic  variants  in  some
way  near  these  genes.  The  association  studies  of  this  era,  collectively  called
candidate gene studies, are notorious for their lack of robustly replicable
results, especially for complex phenotypes [79-82].
The idea that common genetic variation might be responsible for much of
the variation in many interesting traits had important implications for
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genetic association studies. Non-African populations have a limited number
of  common  alleles,  which  are  mostly  shared  across  these  populations.
Furthermore, as the out-of-Africa expansion happened recently (in historical
terms), there has been relatively little time to for recombination to eliminate
the linkage between the alleles. As a result, linkage disequilibrium (LD) is
extensive throughout the human genome. Together, these artefacts of human
population history made it economically possible to use DNA microarray
technology  to  genotype  a  sufficiently  large  number  of  variants  to  reach
genome-wide coverage of common genetic variation, eliminating the need to
select candidate genes or variants for association studies [83]. Relying on LD,
the result of distant relatedness, in effect exploits the giant pedigree
connecting  all  humans.  This  is  similar  to  what  is  made  in  genetic  linkage
studies,  but  without  actually  modeling  the  unknown  shape  of  the  pedigree
and the transmission of alleles within it (Figure 5) [67,84,85].
Figure 5. Association analysis based on LD in the unknown pedigree compared to
linkage analysis in known pedigrees. Reproduced with permission from Tero Hiekkalinna
[85].
A  catalog  of  common  human  genetic  variation  and  an  estimate  of  its
correlation  structure  is  necessary  for  the  design  of  DNA  genotyping
microarrays  that  can  be  used  in  GWA  studies.  The  International  HapMap
consortium produced the first such catalog, partly utilizing other data
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produced prior to the project [54]. Later, the 1000 Genomes Project and the
Haplotype Reference Consortium have collected larger and more
comprehensive catalogs [6,86]. Current efforts expand the coverage of the
catalogs to variants with lower frequencies and new human populations. The
GWA genotyping microarrays almost exclusively assay SNPs, as these are
both numerous and relatively easy to genotype.
In genome-wide association (GWA) studies, a given statistical test of
association between a genetic variant and a trait is independently repeated
for all of the genotyped variants. Linear and logistic regression models are
most often used, as they allow for including covariates in the test. The genetic
variant is typically modeled as a 0, 1, 2 coded variable, which corresponds to
an additive genetic model in simple linear regression and to a multiplicative
genetic model in logistic regression.
Association studies in general and GWA studies in particular are mostly
made using population-based samples of study participants who are assumed
not to be closely related to each other. [75] Although genetic association tests
can be made in any type of study samples, including family-based samples
and pedigrees, it is much easier to recruit a number of unrelated individuals
than to track down similar numbers of people from a single or a few families.
Thus, the typical setting for GWA studies is a population-based cohort. For
disease traits, these cohorts are often collected as case-control cohorts of
affected and unaffected study participants.
The  high  number  of  genetic  markers  used  in  GWA  studies  needs  to  be
taken into account when defining the statistical significance of the results.
Different types of adjustments to the commonly accepted limit of statistical
significance (P=0.05) have been proposed and used. In practice, two are
most often employed: either multiplying the P-values by the number of tests
made (known as the Bonferroni correction) and using the commonly
accepted P<0.05 statistical limit of significance for the Bonferroni-corrected
P-values, or the fixed P<5×10-8 limit of genome-wide significance. The latter
was first put forward as a crude estimate in a seminal article by Risch and
Merikangas [73]. It was later derived by approximating the theoretical
number of independent tests equivalent to testing all common human
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genetic variants, taking into account the non-independence of the real
genetic variants due to LD [87].
A practical consequence of the large number of tests made in GWA
studies is that it nearly guarantees that any systematic biases have plenty of
opportunities to appear in the data. For example, if there are slight
differences in how the DNA samples from affected and unaffected study
participants are handled, it is likely that they will have an effect on at least
some of the thousands of genetic markers studied, possibly creating
artefactual signals of association. Thus, a reasonable study design, including
how the DNA samples are processed and genotyped, and a robust quality
control procedure are required in order to produce valid results.
1.7.4 GENOTYPE IMPUTATION
Modern genotyping arrays are able to query hundreds of thousands of
variants. The resulting data can be further improved by using genotype
imputation to infer the genotypes at untyped genomic positions and
positions where genotype was not successfully determined using the
microarray. One of the benefits of genotype imputation is that it harmonizes
and standardizes data produced on different genotyping arrays, which often
genotype different sets of markers. This enables the combination of multiple
datasets using meta-analysis, resulting in larger effective study samples. [88]
Genotype imputation relies on an external reference dataset consisting of
a set of known (or phased) haplotypes which, together with the genotyped
study data, are fed to an imputation algorithm. Imputation algorithms then
predict the genotypes at those positions which were not present in the study
data based on the reference data. Publicly available reference haplotype
datasets include those produced by the HapMap, 1000 Genomes, and the
Haplotype Reference Consortium projects [6,54,86]. A number of efficient
imputation algorithms have also been developed, making genotype
imputation a routine part of most GWA studies. [88-90]
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1.7.5 LIMITATIONS
There is an important limitation regarding the utility of results from genetic
mapping studies, which is exacerbated in studies of common traits or
common genetic variation: The extensive LD present in human populations
makes it very hard, if not impossible, to attribute associations to single causal
alleles, as alleles in any given genetic region are intercorrelated. In the case of
rare disease alleles with very high penetrances, often located in protein-
coding regions, this is easier, as the causal allele or genotype is almost never
seen in healthy individuals. In the case of common low-penetrance alleles,
however, most of those who carry the disease allele or genotype do not have
the disease. To make the situation even more difficult, most associations
identified using GWAS are related to regulatory variation, not variation in
protein structure. Currently, our understanding of regulatory DNA in the
human genome is far from sufficient to mechanistically understand
regulatory variation. As a result, the results of GWA studies mostly only
indicate  broad  genomic  regions  as  associated  with  a  trait,  but  do  not
unambiguously indicate specific genes or alleles. Scienctists typically try to
conjure ad hoc solutions  to  this  problem,  with  varying  degrees  of  success.
Solving this problem is among the most important current challenges facing
human geneticists. [91]
1.8 HEART FAILURE
1.8.1 DEFINITIONS
Heart failure (HF) is a clinical syndrome that may be caused by a number of
different factors, most commonly ischemic heart disease, hypertension, and
valvular heart disease [2,4]. The different causes lead to a final common
pathway where similar mechanisms are involved, partially independent from
the  aetiology  [92].  The  current  guidelines  of  the  European  Society  of
Cardiology (ESC) define heart failure as "a clinical syndrome characterized
by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that
may be accompanied by signs (e.g. elevated jugular venous pressure,
pulmonary crackles and peripheral oedema) caused by a structural and/or
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functional cardiac abnormality, resulting in a reduced cardiac output
and/or elevated intracardiac pressures at rest or during stress" [4].
Essentially, heart failure is a significant deficit in the heart's pumping
capacity, causing inadequate circulation.
Being a complex clinical syndrome, heart failure can be divided into a
plethora of categories. The different classifications are based on its suspected
aetiology, different physiological parameters, clinical features, temporal
stage and the structural properties of the heart. [4] The classifications are
overlapping and many classifications are often simultaneously used to
describe different types of heart failure [3,4,93].
A central classification of heart failure is based on left ventricular ejection
fraction (LVEF), the percentage of blood pumped out from the left ventricle
with  each  systole.  In  heart  failure  with  preserved  LVEF  (HFpEF),  the
percentage  of  blood  pumped  out  is  considered  normal  (LVEF   50%),
whereas in HF with reduced LVEF (HFrEF) it is smaller than usual (LVEF 
40%). Those cases falling in between the two cut-offs may be classified as HF
with mid-range EF (HFmrEF). [4] HF with preserved and reduced LVEF are
also often called somewhat ambiguously diastolic and systolic HF,
respectively, but diastolic and systolic abnormalities in HF are not mutually
exclusive [4,93].
1.8.2 PREVALENCE
In the vast majority of cases, heart failure is a common late-onset syndrome.
The prevalence of heart failure, or the number of affected individuals, has
been consistently estimated to be roughly 1-2% in developed western
countries. [93] The prevalence increases sharply with age, reaching
approximately  7-8%  in  those  older  than  75  years  [93-95].  Data  from  the
developing  world  are  scarce,  but  heart  failure  is  definitely  not  a  problem of
the affluent western countries alone [3,96,97].
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1.8.3 SYMPTOMS AND DIAGNOSIS
Typical symptoms of heart failure include dyspnea or breathlessness, even
when lying  flat  (orthopnea),  fatigue  and  ankle  swelling.  However,  the  signs
and symptoms may  be  quite  non-specific,  ranging  from nocturnal  cough  to
depression. Diagnosis of HF is therefore often based on ruling out suspected
heart  failure  and  requires  the  presence  of  symptoms,  clinical  findings,  and
objective evidence of cardiac alterations underlying HF. The ESC suggests a
diagnostic algorithm which uses the circulating concentrations of B-type
natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) as a
biomarker to rule out suspected HF (Figure 6). [4]
Figure 6. A diagnostic algorithm for the diagnosis of suspected heart failure as
suggested by the ESC. Modified from [4]. *The ESC guidelines explicitly allow for
uncertainty even at the end of the diagnostic algorithm, indicating that the diagnosis is or
should be confirmed "based on all available data".
1.8.4 NATRIURETIC PEPTIDES IN HEART FAILURE
The atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)
and  small  hormones  are  produced  by  cardiomyocytes  when  they  are
physically stretched. They were discovered relatively recently, in 1985 and
1988 [98,99]. Atrial cardiomyocytes mostly secrete ANP, while ventricular
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cardiomyocytes produce predominantly BNP [100]. Both are created as
prohormones which are cleaved to release a biologically inactive N-terminal
fragment and the C-terminal hormone. For ANP, the cleavage is done by the
cardiomyocytes, which secrete the N-terminal fragment and the active ANP
into the circulation as separate entities. ProBNP is cleaved after entering the
circulation. The main biological functions of ANP and BNP are thought to be
the  reduction  of  cardiac  load  by  increasing  natriuresis,  inducing
vasorelaxation, and other physiological effects. [101]
ANP,  BNP,  and  their  N-terminal  fragments  are  unique  biomarkers  of
heart failure [4,101-103]. During excessive myocardial stress, their
production increases dramatically, even by multiple orders of magnitude.
Thus, their normal circulating concentrations are not compatible with
existing heart failure and they can be used as rule-out criteria. However, high
concentrations  of  circulating  natriuretic  peptides  may  be  caused  by  factors
other than heart failure, most often old age, kidney failure, and atrial
fibrillation, so their elevated concentration is not recommended as a means
to establishing a diagnosis with heart failure. [4,104]
Prior to this thesis, no estimates of the heritabilities of circulating ANP or
BNP concentrations have been published. Candidate gene studies of ANP and
BNP and GWA studies of BNP or NT-proBNP have reported associations at
five genomic loci, showing that their circulating concentrations are indeed
affected by genetic variation [105-110]. The studies have, however, been
limited in their genomic and phenotypic coverage.
1.8.5 AETIOLOGY
Heart  failure  may  be  caused  by  a  number  of  very  different  conditions.  The
ESC divides them into those affecting the heart muscle itself, abnormalities
in the pressure and flow in and through the heart ("abnormal loading
conditions"), and arrythmias disturbing the electrical functioning of the heart
[4]. The conditions can also coexist and one may trigger the onset of another.
[111,112] Quite commonly (even up to 30-50% of the cases by some
estimates), a single underlying cause of heart failure cannot be
unambiguously identified [112,113].
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In the majority of cases, heart failure has a multifactorial aetiology. The
two main causes, coronary heart disease and hypertension, are extremely
prominent and interrelated. [2,114] Together, they account for more than
50% of heart failure cases in all major regions in a recent survey of Africa,
Asia,  the  Middle  East,  and  South  America  [97].  In  the  developed  western
world, these two factors are even more central. Coronary artery disease was
the underlying cause in 62% of the participants in a survey of 24 multicenter
HF treatment trials [115]. An estimate from a western population-based
cohort suggests that total population-wide elimination of hypertension alone
would  have  reduced  the  prevalence  of  heart  failure  by  39%  in  men  and  by
59% in women [2]. Valvular heart disease, where the function of the heart's
valves is impaired, is also a notable cause of heart failure, although its
relative contribution to the prevalence of HF is smaller than that of coronary
artery  disease  or  hypertension  [116].  A  set  of  four  major  modifiable  risk
factors, including blood cholesterol, smoking, diabetes mellitus, together
with  hypertension,  has  an  outsize  impact  on  cardiovascular  disease  in
general, including multifactorial heart failure [117].
1.8.5.1 Hypertension
Arterial hypertension or high arterial blood pressure is commonly defined as
either systolic arterial blood pressure (BP) greater than 140 mmHg or
diastolic arterial BP greater than 90 mmHg [118]. Its heritability has been
estimated  to  be  in  the  range  of  30-70%,  depending  on  the  study  [118,119].
Essential or primary hypertension, which has no specific identifiable cause,
accounts for up to 95% of the cases [120]. However, strong epidemiological
evidence points to excess intake of dietary sodium, typically associated with
urban  or  western  diets,  as  the  main  culprit  in  hypertension  [118,121].
Hypertension is practically absent in remote rural populations where the
intake of dietary sodium is low [122]. It is therefore highly probable that HT
in general, as well as genetic variation in HT susceptibility, are ultimately
related to sodium intake and its physiological effects.
In the absence of a myocardial infarction, hypertension can lead to the
onset of heart failure via complex changes in the structure of the heart. These
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changes  are  related  to  the  need  for  increased  pumping  force  required  to
overcome the high blood pressure. They include ventricular hypertrophy,
where cardiomyocytes increase in size (analogous to the hypertrophy of
skeletal muscle in excercise) and dilation of the ventricles. The events and
mechanisms of how these changes eventually lead to heart failure have been
the focus of extensive studies but remain poorly understood. [123]
Arterial blood pressure, being both of high medical importance and
relatively  easy  to  measure,  is  one  of  the  complex  traits  most  studied  by
human geneticists. Linkage studies of rare Mendelian forms of hypertension
were succesful in identifying rare genetic variants, mostly in kidney-related
genes. However, initial studies assessing typical population variation in BP
with genome-wide linkage studies and candidate gene association studies
were largely a failure until quite recently. [124] Finally, in landmark studies
published  in  2009 and  2011,  large  GWAS meta-analyses  robustly  identified
several  genomic  regions  associating  with  blood  pressure  in  the  general
population [125-127]. Interestingly, and in contrast to the variants identified
in Mendelian HT, these variants appear to be largely unrelated to kidney
function [127].
1.8.5.2 Coronary artery disease and myocardial infarction
Coronary artery disease (CAD), leading to coronary heart disease (CHD), is a
major cause of heart failure. It is a slow, chronic, inflammatory process
comprising the formation of lipid-rich plaques inside the walls of coronary
arteries. The plaques trigger immune cells, particularly macrophages, to
infiltrate the coronary wall towards the plaques. A coronary plaque may
rupture or erode, exposing thrombotic material from inside the plaque to
circulation and causing the formation of a thrombus, also known as a blood
clot. The thrombus in turn may disrupt the flow of blood, leading to the onset
of acute coronary syndromes and ischaemic damage to the part of the heart
which depends on the blood flowing through that particular artery. [128]
Acute coronary syndromes (ACS), comprising acute myocardian
infarction and unstable angina pectoris, are caused by a decrease in coronary
blood flow [129]. The ischemia is often severe enough to lead to the death of
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cardiomyocytes or myocardial infarction (MI). More rarely, the ischaemia
causes chest pain or angina pectoris but no biochemically detectable death of
cardiaomyocytes,  in  which  case  the  ACS  is  labeled  as  unstable  angina
pectoris (UA). MI is further divided into ST-elevation MI (STEMI) and non-
ST-elevation MI (NSTEMI) based on specific electrocardiographic (ECG)
patterns  (Figure  7)  [129,130].  MI  caused  by  the  disruption  of  a  coronary
plaque  is  also  collectively  denominated  MI  type  1,  in  contrast  to  MI  type  2,
where  the  ischemia  is  not  caused  by  CAD  but  other  factors,  such  as  a
coronary embolism [131].
Figure 7. ST-elevation and non-ST elevation myocardial infarction. Transmural
infarction, spanning the entire thickness of the ventricular wall, is reflected as an elevation
of the ST-segment in an electrocardiogram. A subendocardial infarction, with myocardial
injury restricted to myocardium more distant from the blocked artery, may result in no
elevation of the ST segment, its depression, or T-wave inversion. Figure modified from
https://commons.wikimedia.org/wiki/File:Diagram_of_the_human_heart.svg under the
license available at https://creativecommons.org/licenses/by-sa/3.0/legalcode.
CAD may lead to heart failure via myocardial injury related to ischemia in
ACS.  As  the  proliferative  capacity  of  cardiomyocytes  in  adults  is  essentially
absent, myocardium destroyed by an infarction cannot regenerate [132]. The
healing  of  damaged  myocardium  is  therefore  limited  to  the  formation  of  a
fibrotic  scar  and  a  large  infarction  can  directly  lead  to  heart  failure  simply
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due  to  the  quantity  of  cardiomyocytes  lost  [133].  Heart  failure  may  also
gradually develop following an infarction. As the surviving myocardium tries
to compensate for the loss of strength, it is excessively stressed, sometimes
leading to the onset of heart failure, similar to the formation of hypertensive
heart failure. [134]
Although  the  pathological  mechanisms  involved  in  the  formation  of
coronary  plaques  are  complex,  the  development  of  CAD is  simpler  from an
epidemiological  point  of  view.  The  formation  of  coronary  plaques  is  highly
dependent on the circulating concentration of blood lipids, especially
cholesterol contained within low-density lipoprotein (LDL) particles.
[117,128,135] Individuals homozygous for a loss-of-function mutation in the
low-density lipoprotein receptor gene LDLR, causing familial
hypercholesterolemia,  have  a  highly  elevated  risk  of  CAD  and  its
complications [136]. Conversely, LOF mutations in PCSK9, leading to
reduced cellular degradation of LDL receptors and corresponding low
circulating LDL cholesterol concentration, protect their carriers from CAD
[137]. Importantly, diet has been robustly shown to be an important modifier
of blood cholesterol levels [138,139]. Thus, similar to the effect of dietary
sodium intake in hypertension, excess dietary intake of cholesterol is
responsible for a large proportion of CAD cases.
The heritability of CAD, estimated to be roughly 40-60%, is highly similar
to that of hypertension and many other complex phenotypes [140]. Some
cases are essentially monogenic, related to familial hypercholesterolemia, but
the overwhelming majority of cases is related to multifactorial or complex
CAD  [140].  Several  GWA  studies  of  CAD  have  been  published.  Notably,  an
association of a common variant on chromosome 9 with CAD was one of the
first major results of GWAS [141]. Since then, larger meta-analyses have led
to the identification of over 50 additional independent loci [140,142-145].
Emblematic to the difficulty in attributing the results of genetic association
studies  to  specific  causal  alleles,  the  functions  and  mechanisms  of  most  of
these  associations  are  unclear.  Some of  the  associated  loci  can  be  linked  to
cholesterol metabolism, but their majority does not associate with any of the
known common CAD risk factors. [140,146,147]
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1.8.5.3 Takotsubo cardiomyopathy
In the 1990's, Japanese scientists described a peculiar type of transient heart
motion abnormality, disturbing the pump function of the heart. The
symptoms were highly similar to acute coronary syndromes but appeared in
the absence of significant coronary artery occlusion. [148,149] Various names
for the disease, such as stress cardiomyopathy, have been suggested after its
initial description. Takotsubo cardiomyopathy (TTC), the name given by the
Japanese scientists, has however been established in the literature. [149,150]
TTC  often  presents  with  reduced  LVEF  and  has  been  labeled  as  an  acute
heart failure syndrome by some authors [151].
Since TTC has become more widely known, it has been estimated that
roughly  2%  to  7%  of  cases  presenting  with  symptoms  typical  of  ACS  are
instead suffering from TTC, but the cause of Takotsubo cardiomyopathy
remains unknown [149,152]. It is much more common in post-menopausal
women than other parts of the population and often apparently triggered by
a stressful event. In approximately one-third of the cases, the onset is
preceded by an emotially stressful situation. Roughly as often, the stressor is
physical, related to e.g. exercise or a medical procedure. In the remaining
one-third of the cases, no apparent trigger can be readily identified. [153-155]
An  influential  article  published  in  2005  reported  that  acute  TTC
associated with elevated circulating cathecholamine levels [156]. This study
was, however, based on only 19 TTC cases, and its results have not been
robustly replicated. Regardless, the catecholamine hypothesis remains
perhaps the most commonly accepted model for the development of TTC,
although a wide range of alternative explanations have been put forward
[149].
The possible heritability of TTC is very hard to estimate. Being a rare,
late-onset  disease,  both  twin  studies  and  studies  based  on  pedigrees  are
difficult to conduct due to practicalities. Some have suggested that TTC
might have an important genetic contribution, mostly based on isolated
observations of multiple episodes of TTC in single individuals and multiple
cases of TTC in some families [149,155,157-159]. Two candidate gene studies
have  reported  an  association  of  a  SNP  in  the  G-protein  coupled  receptor
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kinase  5  with  TTC,  but  the  strenght  of  the  evidence  is  not  particularly  high
[160,161]. A study using whole-exome sequencing did not detect plausible
rare variants in a sample of 28 TTC cases [162]. Similarly, a recent GWA
study  failed  to  identify  genome-wide  significant  loci  in  a  sample  of  96  TTC
cases and 475 controls  [163].  Thus,  the possible heritability  of  TTC remains
unknown.
1.8.5.4 Other causes of heart failure
Heart failure is sometimes related to exposure to external agents. Radiation
and  some  toxins  can  directly  damage  the  heart  [4].  The  heart  itself  can  be
infected by a virus leading to myocarditis (inflammation of the heart), which
sometimes causes heart failure [164]. An infection by streptococcal bacteria
in the throat can trigger a strong autoimmune reaction known as rheumatic
fever,  which  can  damage  multiple  organs  with  the  valves  of  the  heart  being
among the most easily damaged. The resulting rheumatic heart disease has
been  mostly  eradicated  in  the  wealthy  countries  by  the  timely  use  of
antibiotics, but rheumatic heart disease remains a significant burden in
developing countries. [165] Chagas disease, caused by an infection by the
protozoan parasite Trypanozoma cruzi, is also a regionally important cause
of heart failure in Latin America [166].
A minor but significant proportion of HF is attributable to monogenic
forms caused by rare alleles with high penetrance [167,168]. Among these,
mutations affecting the contractile machinery of cardiomyocytes causing
dilated and/or hypertrophic cardiomyopathies are prominent [168]. Other
monogenic diseases in heart failure comprise channelopathies with
mutations in the ion channels of the cardiomyocyte membrane
(sarcolemma),  proteins  important  to  the  morphogenesis  of  the  heart
associated with congenital heart disease, and mutations in genes related to
neuromuscular disorders. [167,168] A common theme of the monogenic
aetiologies of heart failure is their relatively early onset [167].
To date, more than 50 genes have been implicated in monogenic
cardiomyopathies.  [167,168]  Especially  striking  are  the  high  contribution  of
TTN mutations to the prevalence of dilated cardiomyopathy and the class of
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diseases resulting from mutations in the gene LMNA. Truncating mutations
in TTN, encoding the giant myocardial protein titin, are found in
approximately  1  out  of  every  4  individuals  suffering  from  dilated
cardiomyopathy. [169] Different mutations in LMNA, encoding not one but
three different proteins of the nuclear membrane, cause a staggering array of
10 diverse diseases, including dilated cardiomyopathy [170].
1.8.6 PREVENTION AND TREATMENT
Most cases of heart failure could probably have been prevented.
Interventions in dietary sodium and cholesterol intake alone could decrease
the  burden  of  heart  failure  significantly,  not  only  in  the  rich  western
countries, but also globally. Both primary and secondary prevention have
already  been  succesful  in  some  cases,  such  as  the  North  Karelia  Project  in
eastern Finland [171]. However, much more could still be gained in primary
prevention focusing on the common, modifiable risk factors of cardiovascular
disease.
The treatment of both acute and chronic heart failure partly depends on
its  immediate  cause  but  is  often  similar  regardless  of  the  aetiology.  The
tretment is aimed at alleviating the symptoms and improving the prognosis
of  HF  patients.  Chronic  heart  failure  with  reduced  EF  is  treated  with
angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor
blockers, beta blockers, angiotensin receptor neprilysin inhibitors, and
diuretic drugs, including mineralocorticoid receptor antagonists. In rare
cases, if medical therapy is not alone sufficient, a cardioverter defibrillator or
a cardiac resynchronization therapy device may be implanted or a heart
transplant may be necessary. Treatment of chronic HF with preserved EF is
not well established but can be targeted to alleviate the symptoms and
increase well-being. Patients with arrythmias, e.g. atrial fibrillation, are
treated with anticoagulants to reduce the risk of thromboembolic events,
which is sometimes combined with digoxin to control heart rate. [4]
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2 AIMS OF THE STUDY
The present study aimed at identifying and characterizing genetic variants
associated with traits relevant to the development and diagnosis of heart
failure in the Finnish population. Specifically, the studies comprising this
thesis addressed the following traits:
1) Blood pressure (I, III)
2) Acute coronary syndromes (II)
3) Atrial and B-type natriuretic peptides (III)
4) Takotsubo cardiomyopathy (IV)
MATERIALS AND METHODS
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3 MATERIALS AND METHODS
3.1 STUDY SAMPLES
3.1.1 CHARACTERISTICS AND SAMPLING
The studies comprising this thesis analyzed data from several samples of the
Finnish population, previously collected for epidemiological studies. Some
have  been  designed  and  collected  with  the  explicit  aim  of  studying
cardiovascular disease and its risk factors (COROGENE, TACOS, YFS), while
others are more general surveys of the Finnish population (Health2000,
FINRISK, NFBC, HBCS). Additionally, we used gene expression data from a
cohort of autopsy donors collected in the USA [172]. Some key characteristics
of the samples and cohorts are shown in Table 3.
The national FINRISK study collected cohorts of Finns every five years
between 1972-2012 to monitor the risk factors of chronic non-communicable
disease. The FINRISK cohorts analyzed in the present work (from the years
1992 to 2012) have been recruited from the population aged 25–64 years in
five  different  geographical  regions  of  Finland.  In  each  region,  the  sampling
was stratified for sex and 10-year age groups and random within each
stratum. Together, the FINRISK cohorts form the most comprehensive
epidemiological survey of Finns. [173,174]
The Health2000 survey, similar to the FINRISK cohorts, was collected by
the National Institute for Health and Welfare to monitor the health and well-
being of Finns. The study recruited adult (over 18 years old) participants
from the 15 most populous cities and 65 randomly selected smaller regions. A
subset of the cohort called GenMetS, including participants meeting the
criteria for metabolic syndrome and their matched healthy controls, was
analyzed in the present studies. [175,176]
The Helsinki Birth Cohort Study (HBCS) and the Northern Finland Birth
Cohort (NFBC) study each recruited participants from a specific region in
Finland. The HBCS included participants in Helsinki during 1934 to 1944
and were still living in Helsinki when the cohort was recruited in 1971 [177].
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The NFBC66 cohort recruited the children of women with expected deliveries
in  1966  in  northern  Finland  (the  provinces  of  Oulu  and  Lapland)  with  a
follow-up data collection when the children had reached 1, 14, and 31 years of
age  [178].
The  Cardiovascular  Risk  in  Young  Finns  Study  (YFS)  was  initiated  to
study the risk factors or cardiovascular diseases in the younger part of the
Finnish  population.  In  1980,  it  recuited  a  cross-sectional  sample  of
participants  aged  3,  6,  9,  12,  15,  and  18  years  in  in  Helsinki,  Kuopio,  Oulu,
Tampere, Turku, and their surroundings. While there have been several
follow-ups of the participants, the data for the present study is from the
follow-up made in 2001.
Three of the study samples analyzed collected cardiovascular disease
cases. The COROGENE study recruited consecutive participants assigned to
a coronary angiogram in the Helsinki University Central Hospital (HUCH)
during 2006 to 2008 [179]. Of these, those diagnosed with MI or TTC were
included in the data analyzed in this thesis. The Tampere Acute Coronary
Syndrome Study (TACOS), recruited a consecutive series of participants
admitted to the Tampere University Hospital and diagnosed with ACS during
2002-2003 [180].
In  study  IV,  in  addition  to  the  COROGENE  study  participants,  we
included a sample of TTC cases, collected by the COROGENE investigators.
This sample included retrospective cases recruited using the HUCH
cardiology registry, and four prospective cases enrolled in 2010 [181]. For the
additional sample of TTC cases, children recruited to the population-based
CHILD-SLEEP study were used as controls and genotyped together with the
additional TTC cases [182]. As the study data was from different sources, we
matched the cases and controls based on genotyping array, the first two
genomic principal components, and sex, to create the final study sample.
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3.1.2 GENOTYPING
With one exception (TACOS), the study samples have been genotyped using
various genome-wide genotyping microarrays in multiple laboratories (Table
4).  The  TACOS  study,  used  as  a  replication  cohort  in  the  study  II,  was
genotyped  for  selected  SNPs  using  the  Sequenom  iPLEX  platform
(Sequenom, San Diego, CA, USA).
The genotyping microarrays for the present studies have been supplied by
Illumina (San Diego, CA, USA) and Affymetrix (Santa Clara, CA, USA,
acquired  in  2016  by  Thermo  Fisher  Scientific,  Waltham,  MA,  USA).  The
arrays are based on the hybridisation of target DNA to oligonucleotide probes
and subsequent fluorescent detection of the hybridised DNA [183]. Although
there are differences in the technological details between the manufacturers
and arrays, they produce comparable results which are routinely combined in
GWA studies using suitable statistical methods (e.g. meta-analysis).
3.1.3 ETHICS STATEMENT
All of the studies were conducted according to the principles expressed in the
Declaration of Helsinki with the participants or their custodians giving
written informed consent. The study samples have been reviewed and
approved by their respective ethical committees.
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3.1.4 STUDY PHENOTYPES
3.1.4.1 Blood pressure
Systolic and diastolic blood pressure (SBP and DBP) were measured in each
study cohort by the cohorts' investigators. Hypertension was defined as
having at least one of the following: SBP > 140 mmHg, DBP > 90 mmHg, or
known use of antihypertensive medication. In this study, mean arterial
pressure and pulse pressure were defined as the arithmetic average and the
difference of SBP and DBP, respectively.
3.1.4.2 Acute coronary syndromes
Diagnoses of ACS in study II were from different sources, namely the
COROGENE investigators, the TACOS investigators, and from the Finnish
hospital  discharge  and  cause  of  death  registries.  In  the  COROGENE  study,
ACS was defined as as episode of typical acute chest pain with  50% stenosis
in at least one coronary artery verified with coronary angiography. Those
with  ACS  and  elevated  cardiac  biomarkers  were  diagnosed  with  STEMI  if
they had persistent ST-segment elevations or with NSTEMI if they had either
ST-depression or T-inversions. Additionally, those with typical symptoms
and large  cardiac  enzyme release  (creatine  kinase-MBmass  >  50  mg/l),  but
no significant coronary obstruction, were diagnosed with STEMI. ACS cases
without elevated cardiac biomarkers were diagnosed with UA.
In  TACOS,  the  diagnostic  criteria  were  similar  to  COROGENE,  but
coronary stenosis was not used as a criterium as it was not investigated for a
significant proportion of the study participants. Cases with symptoms or
signs  typical  of  ACS  and  elevated  blood  troponin  (cTnI  >  0.2 μg/L) were
diagnosed  with  either  STEMI  or  NSTEMI  based  on  the  study  participants'
ECG findings. Those presenting without elevated blood troponin were
diagnosed with UA.
For the FINRISK study participants, diagnoses of ACS were retrieved
from the hospital discharge and causes-of-death registries. They are thus
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based on routine clinical work and potentially more heterogeneous than the
diagnoses from the well-defined investigator-led studies. However, published
validation studies have shown that they are of good quality [184].
3.1.4.3 Takotsubo cardiomyopathy
Takotsubo cardiomyopathy was diagnosed by the COROGENE investigators
based on a set of criteria known as the "modified Mayo Clinic criteria". All of
the following conditions were required for a diagnosis with TTC [181]:
1. New electrocardiographic (ECG) change (ST-elevation or T-wave inversion
or both) or cardiac-enzyme release (troponin or creatine kinase) or all of
these
2. Transient hypo-, dys-, or akinesis of the left ventricular midsection with or
without involvement of the apex extending over a single epicardial coronary
vascular bed
3. Absence of obstructive coronary artery disease (coronary luminal
narrowing  less  than  50%)  or  plaque  rupture  confirmed  by  coronary
angiogram (CAG)
4. Absence of myocarditis or pheochromocytoma
3.1.4.4 Natriuretic peptides
Natriuretic  peptide  measurements  for  the  study  III  were  made  in  the
MORGAM Biomarker Laboratory (University of Mainz, Germany) using
three immunoassays: C-terminal B-type natriuretic peptide was measured
using the Abbott Architect i2000 BNP assay (Lake Bluff, IL, USA). N-
terminal proBNP was measured using the Roche Elecsys 2010 proBNP assay
(Roche Diagnostics, Indianapolis, IN, USA). Mid-regional proatrial
natriuretic peptide was measured using the B.R.A.H.M.S. MR-proANP
KRYPTOR assay (B·R·A·H·M·S Aktiengesellschaft, Hennigsdorf, Germany).
[185]
All of the assays used are commercially available. Regrettably, the
manufacturers are not entirely helpful in sharing the specifics of the assays'
63
principles.  The  online  table  "Analytical  characteristics  of  commercial  MR-
proANP, BNP and NT-proBNP assays as per the manufacturer" maintained
by  The  International  Federation  of  Clinical  Chemistry  and  Laboratory
Medicine  (IFCC)  has  proven  to  be  a  valuable  resource  in  this  regard  [186].
While the natriuretic peptide assays have slightly distinct operating
principles,  all  are  immunoassays  utilizing  a  capture  antibody  to  bind  the
target  molecule  into  place  (with  high  affinity)  and  a  detection  antibody   to
measure its quantity in the sample (with high specificity) using optical
detection  [185,186].  See  Figure  8  for  a  schematic  representation  of  the
natriuretic peptide regions targeted by the assays.
Figure 8. Natriuretic peptide assays. The NT-proBNP and MT-proBNP assays bind to
the N-terminal region of the prohormone, whereas the BNP assay binds the C-terminal
region containing the mature hormone. As a significant proportion of circulating proBNP
is uncleaved, the NT-proBNP and BNP assays bind to either the cleaved N-terminal
fragment and the mature C-terminal hormone, or the intact uncleaved prohormone.
ProANP is cleaved prior to secretion and the MR-proANP assay is thought to measure the
concentration of the cleaved N-terminal fragment.
3.1.4.5 Gene expression
In studies II and III, we investigated the correlation between genotypes and
gene expression levels. In study II, we used gene expression measurements
from  the  DILGOM  study,  made  using  the  Illumina  HT-12  array  and  total
RNA extracted from whole-blood samples as previously described [187,188].
The arrays had been background corrected and normalized so that the signal
intensity  distributions  for  all  samples  on  all  arrays  were  equal.  All
participants had been measured using two technical replicates, and nine
participants had been excluded based on poor correlation between the
replicates.
In  study  III,  we  used  gene  expression  data  from  the  Genotype-Tissue
Expression (GTEx) project [172,189]. GTEx has profiled gene expression
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from a multitude of tissues from deceased donors, using RNA sequencing
with a library construction protocol (Illumina TruSeq) that uses polyA
selection.  For  study  III,  we  used  the  GTEx  eQTL  analysis  data  from  left
ventricular and atrial appendage tissue samples (release V6, Oct 6th 2016)
[189].
3.2 STATISTICAL METHODS
3.2.1 GENOTYPE IMPUTATION
Genotype imputation was used in all of the studies comprising this thesis.
Two different  algorithms,  MACH and IMPUTE2,  were  used  in  combination
with different reference panels [190,191]. Both MACH and IMPUTE2
algorithms use a Markov chain Monte Carlo (MCMC) model to impute
missing genotypes based on a set of phased reference haplotypes. A separate
pre-phasing  step  prior  to  imputation  with  IMPUTE2  was  done  with  the
Shape-IT algorithm for a part of the data to speed up the imputation process,
as has been recommended by the IMPUTE2 authors [192].
Althogether, seven different imputation reference panels were used,
reflecting the progression of the imputation methods. The reference datasets
used for all studies contained at least some Finnish participants, with the
exception of the HapMap 2 panel used for a part of the data in the first study.
The reference panels are listed in Table 5.
Table 5. Imputation reference panels.
Panel N N FIN* N variants Studies
HapMap 2 CEU [193] 90 (30 trios) 0 3 204 709 I
1000G Pilot CEU
(8/2009) [194]
60 0 7 724 854 I
HapMap 3 [195] 1 397 0 1 481 135 I
HapMap 3 Finnish [196] 81 81 1 163 280 I
1000G Phase 1
(3/2012) [197]
1 092 93 39 706 715 II,III
1000G Phase 1
(9/2013) [197]
1 092 93 37 878 821 II,III,IV
Custom Finnish [198] 1 941 1 941 13 625 231 III
65
1000G, the 1000 Genomes Project
* N FIN: the number of Finnish samples in the panel
3.2.2 IMPUTATION AND TRANSFORMATIONS OF PHENOTYPIC DATA
Study participants with missing phenotype values were excluded in all
analyses, with the exception of the GWAS for natriuretic peptide traits in
study III. In study III, missing values for BNP and NT-proBNP were imputed
using multiple imputation methods in the "mice" package of R with
subsequent pooling of the results [199,200]. Similar to conventional
imputation resulting in a dataset with the missing values "filled in", multiple
imputation produces multiple imputed versions. It has been reported to be a
robust way to deal with the various potential issues arising from missing
data, particularly when the rate of missingness is large [200]. In retrospect,
as  the  rate  of  missing  data  in  study  III  was  small,  multiple  imputation  was
perhaps an excessive precaution.
The derivation of P-values for standard linear regression assumes the
regression residuals are normally distributed. We thus transformed the
quantitative traits analyzed to achieve normality. For systolic blood pressure
and the gene expression traits (probe intensities), log-transforming the data
resulted in an approximately normal distribution. For the natriuretic peptide
traits in study III, we ensured normality of the traits by using  inverse normal
transformation, which first ranks the observations and then sets the values of
the ranked observations so that they are distributed according to the
standard normal distribution [201].
3.2.3 ASSOCIATION TESTS
We used linear regression as the test of association for quantitative traits
(blood pressure, gene expression, natriuretic peptides) in studies I to III. In
study III, we also used a method based on LASSO regression to fine-map the
loci where we detected a genome-wide significant association.
For the binary disease endpoints in substudies II and III, we used logistic
regression (for prevalent cases) or the Cox proportional hazards model
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(incident ACS cases in study II). In study IV, where the participants were
matched  case-control  strata,  we  used  conditional  logistic  regression  to  take
into account the matching of the study participants into the multiple strata.
The software packages implementing the tests used in the studies are listed
in Table 6.
In substudies I to III, we modeled the genotypes using an addititive
genetic model with the reference homozygotes, heterozygotes, and the coded
homozygotes modeled using 0, 1, 2 coding, respectively. If the variants had
been imputed with uncertainty, we used the expected genotype counts, also
known as "genotype dosages", to take into account the probabilistic nature of
the data. Additionally, in study IV, we made separate recessive and dominant
models, where either the reference homozygote only (for the dominant
model) or the reference homozygotes and the heterozygotes (for the recessive
model) were coded as 0 and the other genotypes as 1.
In substudies II and III, we wanted to assess whether variants associated
with  a  given  phenotype  were  also  associated  with  the  expression  of  nearby
genes. In study II, this was limited to tabulating and plotting the associations
and noting whether they passed a nominal significance limit. In study III, we
developed a more robust approach based on the correlation of variant P-
values and effect sizes. We first refined the set of variants to be included in
the comparison by requiring they are within the genomic region showing an
association to the trait, excluding variants with very different LD patterns in
the samples used for the GWA study and the gene expression tests. We then
investigated the Pearson's correlation between the effect estimates (which do
not depend on allele frequencies) and Spearman's rank correlation for P-
values (which do depend on allele frequencies), deriving the statistical
significance of the comparisons empirically. This approach is documented in
detail in the Supplementary Information for study III.
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Table 6. Genetic association tests.
Study Trait Test Software
(Test)
Software
(Meta-analysis)
I SBP LIN-R ProbABEL,
SNPTEST
MetABEL,
METAv1.2DBP
PP
MAP
II ACS LOG-R,
COX
PLINK,
SNPTEST,
R survival
GWAMA v2.1
Gene Exp. LIN-R SNPTEST -
III Hypertension LOG-R R glm R metafor
SBP LIN-R
DBP
BNP LIN-R, LASSO SNPTEST,
LLARMA,
R glm
R metafor
BNP:NT-proBNP
NT-proBNP
MR-proANP
IV TTC C-LOG-R R clogit R metafor
ProbABEL [202]; MetABEL [202]; SNPTEST [203]; METAv1.2 [204]; PLINK [205]; GWAMA [206]; R glm [207]; R
metafor [208]; LLARMA [209]; R clogit [210]
C-LOG-R, conditional logistic regression; LIN-R, linear regression; LOG-R, logistic regression; LASSO, LASSO
regression
3.2.3.1 Regression models
We included several covariates in the regression models in order to attenuate
any possible confounding and reduce statistical noise in the analysis. All of
the primary analyses were adjusted for the sex of the study participants. We
selected additional covariates based on prior information of their importance
or based on exploratory analyses in the study showing a significant
association (P<0.05) with the analysed trait. Not all of the covariates were
available or relevant for all datasets, so we adapted the specific selection of
covariates  specifically  to  each  data  source.  The  variables  included  in  the
models are listed in Table 7.
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Table 7. Regression models.
Study Trait Covariates
I Blood
pressure
age, sex, smoking habits, alcohol consumption,
body mass index
II MI (GWAS) age, sex, genomic principal components
II MI (TACOS) -
II Incident MI
(FINRISK)
age, sex, genomic principal components, study year,
geographical region, genotyping batch, systolic blood pressure,
blood pressure medication, total cholesterol, HDL-cholesterol,
current smoking, prevalent diabetes
II Gene
expression
none
III Natriuretic
peptides
age, age squared, sex, geographical sampling region,
body mass index, current smoking, systolic blood pressure,
glomerular filtration rate estimated using cystatin C and creatinine
as proxies (eGFR), genotyping batch
III Blood
pressure
age, sex, body-mass index, genomic principal components,
current blood pressure medication use, study year, genotyping
batch
IV TTC sex, genotyping batch, genomic principal components
MI, myocardial infarction; GWAS, genome-wide association study; eGFR, estimated glomerular filtration rate; HDL,
high-density lipoprotein; TTC, Takotsubo cardiomyopathy
3.2.4 HERITABILITY ESTIMATES
We used the GCTA (Genome-wide Complex Trait Analysis) software package
in study III to estimate the proportion of variance in the natriuretic peptide
traits explained by the genome-wide genotype data [211]. This method is
based on first estimating the genetic relatedness between all study
participants  and  then  fitting  a  model  to  the  data  which  expresses  the
observed trait values as a function of the genetic relatedness estimates. The
heritability estimates calculated with GCTA are thus based on genetic
relatedness across the specific set of variants used in the calculations.
Furthermore, the estimates are based on an additive model and thus are
comparable to the "narrow sense" h2 heritability  metric.  The  method  is
analogous to estimating heritabilities using the twin study design or
pedigrees where the genome-wide genetic relatedness is given by the
pedigrees and does not need to be measured.
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3.2.5 ESTIMATES OF STATISTICAL POWER
In study IV, we estimated the statistical power of our study sample using data
from the Finnish participants of the 1000 Genomes Project, using P=5 × 10-8
as the limit for genome-wide statistical significance. To estimate how well
our study genotypes correlated with possible causal variants, we sampled
1,000 variants from each MAF percentile and treated them as causal alleles.
We  identified  the  best  tag  SNPs  in  our  data  in  terms  of  their  r2 with the
causal alleles, only considering directly genotyped SNPs and SNPs with high
imputation  accuracy  (info  >  0.95).  We  varied  the  disease  models
(multiplicative, recessive, dominant) and the genotype relative risks (GRR,
from 1 to 10, increments of 0.25 units) of the causal alleles and, across the
1,000 variants in each MAF percentile, calculated the average power to detect
the association for each GRR, using the best tag SNPs. For the multiplicative
disease model, we used the "GPC" function of the GeneticsDesign R package.
For  the  dominant  and  recessive  disease  models,  we  used  the  "2p2n.test"
function from the pwr package for R. [207] We used 1/5000 as the unknown
disease prevalence parameter and used the the allele frequency and LD
parameter values obtained from the 1000 Genomes Project data. We
multiplied the r2 coefficient by the "info" metric from the imputed analysis
dataset to take into account uncertainty in the imputation.
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4 RESULTS AND THEIR EVALUATION
4.1 STUDY I: BLOOD PRESSURE
Elevated blood pressure increases the risk for many complex cardiovascular
diseases. Such a link has been suspected also for intracranial aneurysms (IA),
rupture-prone pouches in cerebral arteries. Diagnosis of IA, however,
requires significant technological resources (computerized tomography,
magnetic resonance imaging, or cerebral angiography), leading to a lack of
large epidemilogical studies needed to conclusively establish or reject a link
between elevated blood pressure and IA. In study I, we used the suspected
link between elevated blood pressure and IA as a working hypothesis,
predicting that some of the genetic variants associated with IA are in fact
related to blood pressure. We, therefore, aimed at identifying variants
associating with both blood pressure and IA. The successful identification of
such variants would strenghten the hypothesis and, hopefully, lead to the
identification of new blood pressure and IA susceptibility loci. [212]
We selected variants which had shown at least suggestive association with
IA in a recent multinational GWAS (posterior probability for association >
0.1 as estimated by the authors of the IA GWAS) [213]. Altogether, 41
variants from 19 distinct genomic regions passed this threshold and were
included in our study. We used the Health2000 GenMetS study samples as
an initial  discovery cohort,  with a liberal  P-value limit  (P<0.1)  to prune out
variants lacking any association with the blood pressure traits of our study
(SBP, DBP, PP, MAP). We then followed the remaining variants in the YFS,
HBCS,  and  NFBC1966  cohorts.  Finally,  we  queried  the  association  of  our
most statistically significant result in data from the International Consortium
for Blood Pressure Genome-wide Association Studies (ICBP-GWAS).
SNPs in two of  the 19 genomic regions on chromosomes 2 and 5 passed
the  liberal  P-value  threshold  in  H2000.  Of  these,  only  the  three  SNPs
(rs570682, rs2287696, and rs335206) on chromosome 5 were robustly
associated  with  blood  pressure  across  the  Finnish  cohorts  (Table  8;  Figure
9). These SNPs were also associated with blood pressure in the data from the
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multinational ICBP-GWAS consortium. Overall, the association of the SNPs
was more statistically significant for SBP than for the other traits tested. The
statistically most significant association was with rs2287696 and SBP
(P=8.13 × 10-7 in the meta-analysis of the Finns and ICBP-GWAS). The three
SNPs are in strong LD, not only in Finns but also globally, with pairwise D' >
0.8 across the 1,000 Genomes Project Phase 3 data [6]. Thus, the
associations likely represent a single signal tagged by all three SNPs, rather
than multiple underlying causal variants.
The three above-mentioned SNPs are located in one of the introns of the
PR/SET domain 6 gene PRDM6. To inspect this region in detail, we studied
the SBP association of all SNPs present in 1000 Genomes imputed data from
the  four  Finnish  cohorts.  The  region  of  association  covered  the  entire
PRDM6 gene and extended some 150 kbp downstream from its last exon.
Both the location of the BP-associated SNPs and published studies on the
function of PRDM6 led us to attribute the blood pressure association to this
gene. PRDM6 has been reported to mediate the transition of vascular smooth
muscle cells (SMC) from a proliferative to a differentiating phenotype,
inhibiting differentiation and promoting proliferation [214]. This transition
is highly relevant to both hypertension and IAs. Thus, we speculated in the
original publication that the associations we detected stem from a regulatory
effect on PRDM6, increasing its expression and SMC proliferation in the
arterial wall. Unfortunately, at the time of the original study, we did not have
access to high-quality data to confirm of refute this hypothesis.
Recent  data  from the  GTEx consortium,  published  in  2017,  lend  at  least
some  support  to  our  initial  interpretation  of  the  results.  The  A  allele  of
rs2287696, correlated with increased systolic blood pressure and IA risk, is
indeed highly significantly associated with the expression of PRDM6 in
samples from the tibial artery (P=4.9 × 10-7) and aorta (P=2.4 × 10-5) (Figure
10)  [189].  However,  the  direction  of  the  association  is  opposite  to  what  we
predicted in the original publication: The rs2287696 A allele is associated
with decreased, rather than increased, PRDM6 expression. Therefore, based
on this  data  and  the  report  of  PRDM6 promoting  SMC proliferation,  the  A
allele should associate with decreased SMC proliferation.
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Figure 9. Association of rs2287696 with blood pressure in the four Finnish cohorts.
The regression coefficients or betas are shown in mmHg per allele.
Figure 10. Rs2287696 and PRDM6 expression in arterial tissue samples from the GTEx
consortium for the three genotype classes. Figures modified from those retrieved on
1.11.2017 from the GTEx web portal at https://www.gtexprotal.org.
4.2 STUDY II: ACUTE CORONARY SYNDROME
Myocardial injury in acute coronary syndromes is among the most common
causes of heart failure. Elevation of the ST-segment in electrocardiography
during acute myocardial infarction is thought to reflect the transmural
character of myocardial injury. According to this model, STEMI is caused by
a  complete  blockage  of  a  coronary  artery,  while  NSTEMI  results  from
incomplete  or  transient  blockage.  The  elevation  of  the  ST-segment  in
electrocardiography thus reflects a transmural infarction (myocardial injury
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spanning the entire thickness of the heart muscle) caused by complete
blockage  of  a  coronary  artery.  In  contrast,  non-ST segment  elevation  in  MI
reflects subendocardial injury, where the cells closest to the incomplete block
in  the  coronary  artery  near  the  surface  of  the  heart  still  receive  enough
oxygen to survive, but cells deeper within the myocardium suffer from
hypoxia or anoxia. (Figure 7) [215,216]
In study II, we wanted to compare and indentify genetic variants
conferring susceptibility to STEMI or NSTEMI [217]. Although many studies
have been published on the genetics of CAD or MI in general, the division of
MI into STEMI and NSTEMI has received little attention from a genetical
point of view. To address this distinction, we employed GWA analysis in the
COROGENE study sample, stratifying the participants based on whether they
suffered from NSTEMI or STEMI.
The  GWAS  identified  SNPs  on  chromosome  1  associating  with  NSTEMI
showing much weaker association with STEMI (Figure 11, Table 9). Variants
associated with NSTEMI cover a region containing the genes DENND2D,
CEPT1, and DRAM2. The most statistically significantly associated variants
were  located  in  an  intron  of DENND2D, upstream relative to DRAM2 and
downstream relative to CEPT1.
To replicate the GWAS result, we tested the most statistically significant
directly  genotyped  SNP rs656843 for  association  with  STEMI and  NSTEMI
in participants of the TACOS study. Additionally, we also tested it for
association  with  incident  MI  cases  from  the  FINRISK  cohorts.  The
association with NSTEMI replicated in TACOS. It was also similar in
direction in the smaller set of incident cases from FINRISK, i.e. the the risk
allele  was more common in NSTEMI cases,  but in FINRISK the association
was not statistically significant (P=0.43).
The overall most statistically significant association was with NSTEMI
when we  combined  the  results  from the  case-control  samples  (COROGENE
and TACOS) using meta-analysis (rs656843; odds ratio 1.57, P=3.11 × 10í10).
We followed this  result  in non-Finnish populations by examining data from
two large international GWAS meta-analyses of coronary artery disease,
where rs656843 did not show any statistically significant association
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(P>0.05). The locus was, therefore, genome-wide significant and replicated
for  NSTEMI  in  Finns  but  did  not  associate  with  CAD  in  two  international
meta-analyses.
Figure 11. Association of genetic variants with MI on chromosome 1. Genes are
depicted as annotated in the RefSeq database. Potential regulatory sites, indicated by
histone 3 lysine 27 acetylation (Layered H3K27Ac), as reported by the Encode consortium,
are shown under the genes [28,29]. Linkage disequilibrium is shown calculated from the
directly genotyped SNPs of the GWAS sample.
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Table 9. Association of rsr656843 with MI
Trait Sample MAF Controls
(N)
MAF Cases
(N)
OR*
(95% CI)
P
NSTEMI COROGENE
0.15
(1,576)
0.21
(962)
1.63
(1.38-1.93)
1.22 × 10-8
TACOS
0.14
(566)
0.19
(389)
1.44
(1.12-1.86)
0.0049
Case-control
combined†
0.15
(2,142)
0.20
(1,351)
1.57
(1.36-1.81)
3.11 × 10-10
FINRISK
0.17
(16,143)
0.18
(163)
1.13
(0.84-1.51)
0.43
STEMI COROGENE
0.15
(1,576)
0.16
(614)
1.07
(0.88-1.29)
0.5
TACOS
0.14
(566)
0.17
(173)
1.27
(0.91-1.77)
0.16
Case-control
combined†
0.15
(2,142)
0.16
(787)
1.11
(0.94-1.31)
0.2
FINRISK
0.17
(16,143)
0.16
(99)
0.97
(0.65-1.43)
0.87
All MI COROGENE
0.15
(1,576)
0.19
(1,579)
1.33
(1.15-1.54)
1.27 × 10-4
TACOS
0.14
(566)
0.18
(562)
1.38
(1.10-1.74)
0.0062
Case-control
combined†
0.15
(2,142)
0.19
(2,141)
1.34
(1.19-1.52)
2.58 × 10-6
FINRISK
0.17
(16,143)
0.16
(484)
1.00
(0.84-1.19)
0.98
MAF, minor allele frequency; OR, odds ratio; MI, myocardial infarction; STEMI, ST elevation myocardial infarction;
NSTEMI, non-ST elevation myocardial infarction;
Case-control samples were analyzed using logistic regression including age, sex, and the first ten genomic principal
components (COROGENE) or no covariates (TACOS) in the model. FINRISK was analyzed with the Cox
proportional hazards model stratified by study year, geographical region, and genotyping batch with gender, systolic
blood pressure, blood pressure medication, total cholesterol, HDL-cholesterol, smoking, and diabetes used as
covariates.
* For FINRISK, the effect is reported as the hazard ratio
† Results from COROGENE and TACOS combined using inverse-variance weighted fixed effects meta-analysis
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Unequal sample sizes in the GWAS would be the simplest explanation for
observing a more statistically significant association for NSTEMI (N=962)
than  for  STEMI  (N=614).  The  association  was,  however,  statistically  less
significant when analyzing both MI types together, despite the larger sample
size in this analysis setting. To formally investigate whether the effects were
different for NSTEMI and STEMI, we calculated posterior probabilities of
statistical  models  where  rs656843 conveyed  either  no  risk,  the  same risk,  a
higher risk for NSTEMI, or risk only for NSTEMI. Out of  these models,  the
latter two with risk specific to NSTEMI alone (posterior probability 0.71) or a
related but smaller risk for STEMI (posterior probability 0.29) were the most
probable. The effect underlying the association, therefore, appeared either
specific to or at least stronger for NSTEMI.
Although other causes do exist, both NSTEMI and STEMI are, in general,
mostly complications of CAD. Furthermore, the COROGENE study
participants had been studied using coronary angiography, confirming CAD
as  the  probable  cause  of  the  MI.  The  stronger  association  observed  with
NSTEMI, however, cannot simply be explained as arising from increased
susceptibility to CAD, as such an effect should affect both STEMI and
NSTEMI in a similar manner. To confirm this, we explored the associations
of variants previously reported with GWAS for CAD or MI. A total of 50 such
SNPs  were  present  in  our  GWAS  data.  None  of  them  showed  statistically
significant differences in allele frequencies between the STEMI and NSTEMI
cases when the P-values were Bonferroni corrected for the 50 tests made. The
NSTEMI association detected in Finns was, therefore, quite different than
the previously identified CAD risk loci.
The most statistically significant difference in STEMI vs. NSTEMI for the
previously published CAD or MI risk SNPs was with rs514659. Intriguingly, it
was  also  the  only  SNP  among  the  50  specifically  associated  with  MI  in  the
presence of CAD rather than the risk for CAD  [218]. The C allele of rs514659
was slightly more common in STEMI cases (C allele frequency in STEMI
patients  48.06%  vs.  43.26%  in  NSTEMI;  P=0.0066).  Rs514659  tags  one  of
the  genetic  variants  responsible  for  the  ABO  blood  groups,  the  C  allele
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correlating with the O blood group. This data may suggest that the O blood
group associates with larger risk for STEMI than for NSTEMI.
Typical  of  GWAS,  the  SNPs  associating  with  NSTEMI in  our  study  were
not  predicted  to  change  the  amino-acid  sequence  of  proteins  coded  by  the
genes in the locus. This suggests that the NSTEMI association depended on
an underlying effect on gene expression. To test this hypothesis, we used
RNA expression data measured from whole blood in 513 healthy participants
of the DILGOM study, an extension of FINRISK 2007. We tested the SNPs in
the region for association with the expression of the nearby genes and
identified two independent signals for the expression of DRAM2. The
primary signal was much stronger but did not correlate with the association
of the SNPs with NSTEMI. The secondary signal, detected when we set the
most significant DRAM2 expression SNP as a covariate, was statistically
weaker but was somewhat correlated with the results for NSTEMI. These
results are somewhat inconclusive, although they offer at least some support
to the interpretation that the NSTEMI association may be related to the
expression of DRAM2.
4.3 STUDY III: NATRIURETIC PEPTIDES
Atrial and B-type natriuretic peptides (ANP and BNP) are unique biomarkers
of heart failure. Despite their prominence in cardiovascular physiology,
including diagnostics and attempts at using them as therapeutic agents,
surprisingly few studies have addressed their role in humans during
approximately normal homeostatic conditions. [101,219] In study III, we
investigated the relationship between genetic variation, natriuretic peptides,
and blood pressure in the general population (Table 10). Specifically, we used
GWA analysis to study the circulating concentrations of midregional
proatrial natriuretic peptide (MR-proANP), BNP, and N-terminal proBNP
(NT-proBPN).  As  proBNP  is  cleaved  in  the  circulation  after  it  has  been
secreted by cardiomyocytes, we also analysed the ratio of BNP to NT-proBNP
concentrations as a proxy of their processing in the circulation [101].
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We first estimated the SNP-based heritabilities of the traits. The point
estimates of  phenotypic variance explained by our entire genome-wide data
ranged from 13.9% for MR-proANP to 23.0% for NT-proBNP (Table 11).
Most  of  the  variance  was,  therefore,  explained  by  factors  other  than  the
genetic variation captured by our dataset, but all traits had a moderate
genetic contribution as well. The precision of the estimates we obtained was
coarse, preventing a meaningful comparison between the four traits.
We detected genome-wide significant associations in four genomic loci
(Figure 12, Table 12). Replication of the associations was statistically
significant for all but one of the loci (rs701041 on chromosome 12 near the
nuclear receptor corepressor 2 gene NCOR2). Fine-mapping the successfully
replicated loci identified five independent variants in the associated region
on chromosome 1, two independent variants in the chromosome 12 locus,
while a single signal explained the association on chromosome 8. Thus, a
total of eight independent variants in three genomic regions associated with
at least one of the natriuretic peptide traits of our study.
On chromosome 1, the natriuretic peptide associated SNPs were located
in  and  around  the  adjacent  genes NPPA and NPPB, which encode proANP
and proBNP, respectively. Associations with natriuretic peptides have been
reported  in  this  region  previously,  but  the  prior  studies  did  not  have  both
high-resolution genomic coverage and mesurements for both ANP and BNP,
and had been unable to specifically attribute the associations to either ANP
or BNP [106,108-110,220]. In our study, we were able to divide the
associatied  variants  into  those  associating  with  MR-proANP  and  those
associating with BNP or NT-proBNP. None of the SNPs associated with both
ANP and BNP, which is somewhat surprising taking into account that NPPA
and NPPB are separated by less than 10 kbp.
Three of the five indepently associated SNPs on chromosome 1 associated
with the circulating concentration of MR-proANP. They are located
approximately 40 kb downstream from NPPA, within the transcribed regions
of the genes MTHFR and C1orf167. We estimated that the effect sizes of these
three SNPs were approximately 2.5 to 5.0 pmol/L. The median MR-proANP
concentration of the GWAS samples was 41.3 pmol/L  (interquartile range
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25.2 pmol/L), so the effects of the SNPs were quite substantial compared to
typical  values  in  the  study  population.  Comparing  the  association  of  SNPs
with MR-proANP with their effect on gene expression in left ventricular and
atrial appendage tissue samples from the GTEx consortium indicated that, as
expected, the SNP effects for MR-proANP and the expression of NPPA were
positively correlated (Figure 13). The SNPs detected as associated with MR-
proANP are, therefore, likely related to regulatory variants affecting the
expression of NPPA in the heart.
Two  independent  SNPs  on  chromosome  1  associated  with  BNP  or  NT-
proBNP.  Rs198379  associated  with  both  BNP  and  NT-proBNP,  with  an
estimated effect size of 4.5 pg/mL (for BNP) and 9.6 pg/mL (for NT-proBNP)
per allele. The other SNP, rs61761991, was extremely significantly associated
with NT-proBNP (P=8.76 × 10-68) and BNP:NT-proBNP ratio (P=4.81 × 10-
103)2 but did not associate with C-terminal BNP. The two SNPs had thus very
different association profiles. Rs198379 showed, as expexted, an association
to measurements both from the C-terminal and N-terminal ends of proBNP.
The association of SNPs with BNP was also correlated with their association
to expression of NPPB in the heart, indicating the presence of an underlying
causal variant affecting NPPB expression (Figure 13). Rs61761991, however,
only associated with the N-terminal measurement.
Rs61761991  is  an  amino-acid  changing  SNP  located  in  the  N-terminal
proBNP prohormone (NP_002512.1:p.Arg72His). This region is  used as the
antigen to prepare the capture antibody for the NT-proBNP assay employed
in  our  study  (and  apparently  most  other  NT-proBNP  assays  as  well)  [186].
Rs61761991 appeared to effectively block the signal of the NT-proBNP assay,
as those heterozygous for this SNP had roughly 50% smaller NT-proBNP
values on average than the common homozygotes (Figure 14). The rarer T
allele of rs61761991 is practically absent in most populations but enriched in
Finns  where  the  its  frequency  is  roughly  3%  [221].  Assuming  Hardy-
Weinberg equilibrium, we can thus estimate that approximately one in
twenty Finns are rs61761991 heterozygotes and should present a measured
2 4.81  ×  10-103 = 0.00000 00000 00000 00000 00000 00000 00000 00000 00000 00000
00000 00000 00000 00000 00000 00000 00000 00000 00000 00000 00481
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concentration of NT-proBNP some 50% lower than extrapolated from the
corresponding C-terminal BNP value. One in every thousand Finns is
expected to be a TT homozygote with very small measured NT-proBNP
concentration, regardless of the circulating BNP concentration.
SNPs on chromosome 8 associated with BNP:NT-proBNP ratio and NT-
proBNP, but not with MR-proANP or BNP. Of these SNPs, the most
statistically significant SNP in the GWAS was rs7000551. The SNP is located
in  an  intron  of  solute  carrier  family  39,  member  14  gene SLC39A14,
approximately 20 kbp upstream from the protein phosphatase 3 catalytic
subunit gamma gene PPP3CC. We did not detect statistically independent
secondary associations in this locus, suggesting that the signal we detected
relates to a single causal allele correlated with rs7000551. Gene expression
data from GTEx indicated that the BNP:NT-proBNP associated variants on
chromosome 8 also correlated with the expression of PPP3CC in both
ventricular and atrial tissue samples (Figure 13). Alleles associated with
increased  BNP:NT-proBNP  ratio  correlated  with  reduced  expression  of
PPP3CC.
Protein phosphatase 3, also known as calcineurin, has been shown to be
an important regulator of cardiac hypertrophic signaling [222]. It is an
enzyme consisting of three subunits: a catalytic subunit, a regulatory subunit,
and a subunit known as calcineurin A. In humans, there are three alternative
catalytic subunits (alpha, beta, gamma), with PPP3CC encoding the gamma
catalytic subunit. Differences in PPP3CC expression should, therefore, be
reflected as differences in the relative abundancies of calcineurin isoforms.
This data indicates that the association of SNPs on chromosome 8 near
PPP3CC with the BNP:NT-proBNP ratio may relate to differences in PPP3CC
expression in the myocardium.
The third genome-wide significant locus we detected was located on
chromosome  12.  A  prior  study  had  reported  an  association  with  an  SNP  in
this region with NT-proBNP [107]. In our data, we identified two
independent  SNPs  in  this  locus,  both  associated  with  NT-proBNP  and  the
BNP:NT-proBNP ratio. Similar to the chromosome 8 locus near PPP3CC, the
chromosome 12 SNPs did not associate with BNP or with MR-proANP.
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Comparison with gene expression failed to highlight any of the genes in the
region as likely candidates. The authors of the previous study had pointed to
the polypeptide N-acetylgalactosaminyltransferase 4 gene GALNT4 located
in the NT-proBNP associated region as a potential culprit, as it initiates O-
linked  glycosylation  and  proBNP  is  known  to  be  glycosylated  [107].  Our
observation of no association with BNP offers some support to this idea, as
the C-terminal region containing the active hormone is not glycosylated.
Natriuretic peptides are thought to be important regulators of blood
pressure. We explored this by testing the genetic variants identified with
natriuretic peptide GWAS for association with blood pressure in multiple
population-based  cohorts  of  Finns,  identifying  a  weak  but  consistent
association with BP for the MR-proANP SNPs. The SNPs associated with
BNP, NT-proBNP, or their ratio did not associate with blood pressure in our
data. The MR-proANP increasing SNP alleles associated with approximately
0.25 mmHg (diastolic BP) and 0.50 mmHg (systolic BP) differences in blood
pressure.
To  assess  the  combined  effect  of  the  three  MR-proANP associated  SNPs
on blood pressure, we formed a summary variable summing the number of
MR-proANP increasing alleles for all three SNPs (thus ranging from 0 to 6).
This variable explained 2.36 % of the variance in MR-proANP concentration
and associated with a 9 % decrease in the odds ratio for hypertension
(OR=0.91; SE=0.0283; P=8.2 × 10-4). We also estimated the fraction of
hypertension cases attributable to the three-SNP allele counting variable as
11.8%, surprisingly high given the moderate effects of the individual SNPs on
blood pressure. Thus, a moderate decrease in MR-proANP was estimated to
substantially increase the prevalence of hypertension in our study samples.
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Table 10. Sample characteristics in the natriuretic peptide study.
GWAS
Sample*
Replication
Sample*
Blood Pressure
Study Sample†
N 4,932 1,373 27,059
Age (years) 46.18 (21.39) 48.67 (20.5) 42.41 (25.42)
Females (n/%) 2,592 (52.55%) 711 (51.78%) 14,377 (53.13%)
Body Mass Index (kg/m2) 25.73 (5.473) 25.97 (5.116) 25.69 (5.714)
Diastolic Blood Pressure
(mm Hg)
82 (15) 82 (14) 80 (16)
Systolic Blood Pressure
(mm Hg)
132 (26) 134 (26) 130 (25)
Hypertension (n/%) 2,090 (42.38%) 605 (44.06%) 10,404 (39.3%)
Smoking (n/%) 1,230 (24.94%) 300 (21.85%) 3,893 (24.9%)
Prevalent Heart Failure
(n/%)
0 (0%) 0 (0%) na.
Incident Heart Failure (n/%) 289 (5.86%) 84 (6.118%) na.
NT-proBNP (pg/ml) 39.26 (56.49) 46.75 (57.2) na.
MR-proANP (pmol/L) 41.3 (25.2) 43.4 (25.4) na.
BNP (pg/ml) 12.9 (17.6) 14.9 (19.6) na.
Quantitative variables are shown as median (interquartile range), quantitative variables as count (proportion).
* Study participants from the FINRISK 1997 cohort
† Study partipants from the FINRISK 1992, FINRISK 2002, FINRISK 2007, NFBC66, HBCS, and Health2000
cohorts
Table 11. Natriuretic peptide variance explained by the genome-wide genotype data.
Trait Variance Explained Standard Error
MR-proANP 0.139 0.071
BNP 0.135 0.07
NT-proBNP 0.23 0.072
BNP:NT-proBNP 0.179 0.071
Figure 12. P-values in the genome-wide significant loci for natriuretic peptides. Note:
Y-axis cut at Y=18 and data shown for genome-wide significant regions only.
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Figure 13. Effects of variants on natriuretic peptides and gene expression. The effect
size estimates for the natriuretic peptide traits (X axis) and gene expression (Y axis) are
shown for the genes NPPA, NPPB, and PPP3CC. For each gene, the panels titled AA and
LV show the values for samples from atrial appendage and left ventricular tissue,
respectively. Black dots show the SNPs included in the analysis. Red dots depict SNPs
excluded from the analysis based on differences in LD structure between the natriuretic
peptide study sample (from Finland) and the gene expression study sample (from USA).
Figure 14. BNP and NT-proBNP distribution by rs61761991 genotype.
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4.4 STUDY IV: TAKOTSUBO CARDIOMYOPATHY
Takotsubo cadiomyopathy (TTC) is a distinctive condition often presenting
with transient heart failure. A genetic predisposition to TTC has been
suggested in the literature, but previous genetic studies of TTC have been
inconclusive  or  unconvincing  [223-228].  We  conducted  a  GWAS  of  TTC  to
investigate the possible contribution of genetic variation to TTC susceptibility
and to systematically replicate previously reported results.
Our GWAS did not detect genome-wide significant loci (Table 13). The
most statistically significant variant was rs7897505 near the cGMP-
dependent protein kinase 1 gene PRKG1 (rs7897505,  odds  ratio  0.30,  P  =
1.04 × 10-6). PRKG1 mediates cardiovascular cGMP signalling and affects
cardiomyocyte function, suggesting a plausible biological context for the
result [229]. The association is, however, far from statistically significant.
None of the previously reported results replicated in our material.
Notably, this included the only previously published genetic association
result which has been independently replicated (albeit in a small sample of
only 20 TTC patients) [226,227]. The original result was reported by Spinelli
et al.,  who associated the L41Q polymorphism rs17098707 in the G protein-
coupled receptor kinase 5 gene GRK5 with TTC risk [227]. Both the original
study and the later replication were performed in Italy, although neither
specified the ethnic background of the study participants. However, the allele
associated by these studies with TTC is rare in most non-Africans (frequency
from 1 to 2 %), but common in at least some African populations (frequency
from 24 to 36 %). In a sample of 107 Italians from Tuscany, the frequency of
the  allele  was  only  2.3  %.  [6]  Spinelli  et  al.  reported  a  surprisingly  high
frequency of the L41 allele in TTC patients as well as their control sample
(376 unaffected volunteers; frequency of the L41 allele 23.9 %), roughly 10-
fold  the  estimate  from the  Tuscan  sample.  The  results  from the  two  Italian
study samples are thus difficult to interpret. The L41 allele was rare and did
not associate with risk for TTC in our study, consistent with the results from
a study of 92 Australian TTC patients [224].
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Prior to our study,  one GWAS of  TTC has been published by Eitel  et  al.,
reporting 18 loci as suggestively (i.e. not genome-wide significantly)
associated with TTC [223]. None of these replicated in our study material
when the P-values were adjusted for the 18 tests  made.  When we combined
the results from Eitel et al. with those from our study sample using meta-
analysis, all but one of the 18 loci had pointwise P-values greater than 0.05
(Table  14).  The  only  variant  which  was  nominally  (but  not  genome-wide)
significant in the meta-analysis was rs113154180 (odds ratio=1.97 [95%
confidence  interval  1.24  to  3.132],  P=0.0041).  This  SNP  is  located  in  an
intron of the glutamate metabotropic receptor 7 gene GRM7.
Given that the onset of TTC is often linked to emotional or psychological
stress, the location rs113154180 in GRM7 is intriguing, as GRM7 knockout
mice have a deficit in an amygdala-dependent fear response. Similarly,
blocking GRM7 using a pharmacological antagonist in mice inhibits stress
and anxiety-related behavior while reducing amygdala plasticity. Although
the  association  of  rs113154180  with  TTC  is  not  statistically  significant,  it  is
currently the only genetic variant showing some association in two
independent studies with genome-wide coverage of genetic variation.
Rs113154180 may thus be the top candidate TTC susceptibility locus so far.
Aided  by  Finnish  whole-genome  sequencing  data  from  the  1,000
Genomes Project,  we estimated the statistical  power in our study sample to
detect an association for disease alleles with different effect sizes, allele
frequencies, and modes of inheritance (Figure 15). This analysis suggested
the dataset was well-powered to detect common risk alleles conferring a high
relative  risk.  Two examples  of  such  alleles  for  other  diseases  are  the  APOE
epsilon alleles in late-onset Alzheimer's disease (rs4420638; MAF=0.27; OR
95%  CI  =  3.56  to  4.14)  and  a  regulatory  variant  near  the RET gene in
Hirschsprung's disease (rs2435357; MAF=0.26; OR 95% CI = 3.2 to 4.7)
[230,231]. Statistical power to detect a genome-wide significant association
was practically nonexistent for variants with relative risks smaller than 3,
regardless  of  their  frequency  or  mode  of  inheritance.  Power  to  detect  an
association for the loci reported by Eitel et al., with less stringent corrections
for multiple testing, was adequate (Figure 16). The negative results from the
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GWAS, together with the analysis of statistical power, mostly rule out the
presence of common, high-risk alleles for TTC in our study population.
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Figure 16. Statistical power in the data for replicating the results of Eitel et al. (alpha =
0.05/18) and for detecting a nominally significant association (alpha = 0.05). Figures are
shown assuming a multiplicative mode of inheritance.
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5 GENERAL DISCUSSION
5.1 BLOOD PRESSURE AND PRDM6
In study I, the working hypothesis predicted shared genetic risk for high
blood pressure and intracranial aneurysms. The identification of blood
pressure  loci  had,  at  that  point  in  time,  proven  to  be  surprisingly  difficult,
even  with  large  sample  sizes  [125-127].  We  suspected  that  prioritizing
variants  based  on  results  from a  GWAS for  IA  could  be  used  to  detect  new
blood pressure loci and, at the same time, establish a genetic connection
between the two traits.
We  successfully  detected  a  novel  locus  associated  with  blood  pressure
near the gene PRDM6, at least partly validating our hypothesis. However,
this  was  the  only  locus  of  those  selected  for  the  study  showing  such
association. Notably, loci which were genome-wide significantly associated
with  IA  in  the  prior  GWAS  did  not  associate  with  blood  pressure.  Shared
genetic risk for the two traits was thus the exception rather than the rule.
Although  the  inherent  limitations  of  genetic  association  studies  make  it
difficult to attribute associations to specific genes, previously published
results point to PRDM6 as a plausible candidate. Recent data from GTEx also
show that the blood-pressure-associated SNP is indeed associated with
PRDM6 expression in arterial samples [189]. The role of PRDM6 in vascular
smooth muscle cells suggest that the blood pressure association may stem
from  an  effect  on  the  structure  of  the  arterial  wall.  Contrary  to  our
speculation in the original publication, the SNP allele associated with
elevated blood pressure correlates with decreased PRDM6 expression in
arterial samples. The genetic variant associated with elevated blood pressure
may thus be related to decreased vascular smooth muscle cell proliferation.
In the original publication for study I, we suggested that the approach of
using analysis results for a related trait (e.g. IA) as a starting point could be a
general strategy to identify genetic variants associated with a trait of interest
(e.g. blood pressure). This has, however, not been a common trend since the
study was published. Rather than modifying study designs, complex trait
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genetics has mostly progressed by collecting larger study samples in
international consortia. For blood pressure, recent meta-analyses from such
studies have covered nearly half a million study participants [232,233].
5.2 STEMI AND NSTEMI
To the author's knowledge, study II is still the only published genome-wide
study with stratification of ACS into STEMI and NSTEMI. In fact,
remarkably few studies, genetic or otherwise, have tried to identify why some
get  one  of  the  subtypes  rather  than  the  other.  This  is  likely,  at  least  partly,
explained by both having the same underlying main cause, coronary artery
disease. Anecdotal evidence, based on personal discussions with medical
doctors,  suggests  that  many  regard  the  specific  type  of  MI  to  be  caused  by
somewhat  random  factors  or  coincidences,  such  as  the  details  of  plaque
rupture.  Suggesting  that  the  difference  is  partly  a  deterministic  result  of
systematic underlying processes is generally taken as somewhat provocative.
Study  II  identified  a  genetic  variant  which  had  a  much stronger  risk  for
NSTEMI than for STEMI on chromosome 1 near DRAM2. The difference was
large enough for the signal to meet genome-wide significance only when we
analysed the NSTEMI cases. The combined analysis setting, comparing all
acute MI cases to the controls, did not detect the association. In a formal
comparison, the data was even compatible with the risk being specific to
NSTEMI.
The association on chromosome 1 with NSTEMI was not present in large
international meta-analyses of coronary artery disease [144,145]. Although
they analysed a more heterogeneous phenotype, a reasonable proportion of
their study samples had been diagnosed with MI. It seems unlikely these
large meta-analyses missed the association solely because they analyzed
cases diagnosed with CAD rather than NSTEMI. The association detected in
Finns may depend on a genetic variant which is somewhat more common in
the Finnish population and too rare elsewhere to be detected using a
multinational study sample. Alternatively, the large multinational studies
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may  have  missed  the  association  due  to  some  statistical  properties  of  their
much more heterogeneous data.
RNA expression data from whole-blood samples indicated that the
NSTEMI  association  might  be  related  to  an  effect  on  the  expression  of
DRAM2. Whole blood, however, is probably not the ideal tissue to study this
connection and coronary artery or myocardial tissue samples would have
been more relevant. For practical reasons, however, they were not available.
A key difference in the pathology of STEMI and NSTEMI is the extent of
coronary artery occlusion. In STEMI, it is presumed to be complete, whereas
in NSTEMI it is thought to be partial or transient [215,216]. In partial
occlusion, a gradient of oxygen availability forms along the area depending
on blood flowing through the partially blocked artery. Cells at the top of the
gradient near the blocked site suffer less hypoxia, while cells at the bottom
receive  too  little  oxygen  to  survive,  leading  to  the  infarction.  An  intriguing
idea  is  that  the  genetic  NSTEMI  association  is  somehow  related  to
myocardiocytes' capacity to survive during hypoxia. Silencing DRAM2 has
been shown to interfere with cell death in vitro in  tumor  cells,  but  the
relevance of this observation is unclear in the context of differentiated, non-
proliferating cardiomyocytes [234].
5.3 NATRIURETIC PEPTIDES AND BLOOD PRESSURE
Natriuretic peptides ANP and BNP were discovered in the 1980's. This is
much later than most other hormones - testosterone and estrogen, for
example,  were  discovered  half  a  century  before  ANP and BNP [235].  Being
relative newcomers, the understanding of the physiological functions of ANP
and BNP is less complete as compared to more well-known hormones.
Several curious observations have been made for ANP and BNP. In mice,
overexpression of either NPPA or NPPB triggers hypotension, and knocking
out NPPA leads to hypertension [236-238]. Surprisingly, knocking out NPPB
triggers  cardiac  fibrosis,  not  hypertension  [239].  In  humans,  the  effects  of
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ANP or BNP infusions vary based on baseline status. In patients suffering
from HF, infusions of ANP or BNP trigger various changes, including a
decrease in arterial pressure, but in healthy males only induce natriuresis
with no effect on arterial BP [219,240-242]. In those suffering from essential
hypertension, both ANP and BNP have been reported to be hypotensive with
BNP surprisingly showing up to threefold greater potency than ANP, even
though  both  have  similar  receptor  affinities  [243,244].  In  obese  men,  ANP
and blood pressure show no association or even an unexpected negative
association [245].
Our results show that genetic differences in circulating ANP
concentrations had a small but significant effect on arterial blood pressure.
The combined effect of the three MR-proANP associated SNPs identified in
the study associated with a significant difference in risk for hypertension.
Prior studies had shown a link between genetic variation near NPPA and
NPPB,  but  due  to  the  limitations  of  their  data,  they  have  not  been  able  to
attribute the associations to either [109]. Our data, combined with gene
expression data from myocardial samples, show that genetic variants
increasing the expression of NPPA in the myocardium associate with greater
circulating concentration of MR-proANP, lower arterial blood pressure, and
reduced risk of hypertension in the general population.
Contrary to ANP, our results did not show an association with genetic
differences in circulating BNP concentration and arterial blood pressure.
This, however, does not mean that BNP has no such effect. Being a study of
naturally  occurring  genetic  variation,  the  results  are  limited  to  observing
whatever genetic variants were present in our study population. The effect of
the  BNP-associated  SNP  may  have  been  too  small  to  cause  a  large  enough
difference  in  blood  pressure  to  be  detected  in  our  study.  That  said,  data  on
the effects of BNP in the general population are scarce. Previously published
genetic studies near NPPA and NPPB have  been  used  in  the  literature
ambiguously  to  make  a  case  for  both  ANP  and  BNP  as  blood  pressure
regulators [246,247]. Our study shows that the genetic results only
specifically support ANP and are, at most, uninformative for BNP.
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In addition to the NPPA-NPPB locus, three loci elsewhere in the genome
have been associated with circulating natriuretic peptide concentrations,
including the PPP3CC locus discovered in study III [107]. Our results show
that a common characteristic of these loci is their association to NT-proBNP
rather than C-terminal BNP. For the PPP3CC locus,  the  association  was
strongest for the ratio of BNP to NT-proBNP. These loci may be related to the
processing of proBNP in the circulation. Contrary to proANP, which is
cleaved by the cardiomyocytes secreting the hormone, proBNP is cleaved
peripherally and a large proportion of circulating BNP is actually contained
in uncleaved proBNP [101,248]. Nonspecific mechanisms related to the
elimination of circulating polypeptides from the blood, e.g. kidney function,
might  influence  BNP:NT-proBNP ratio.  However,  the  loci  did  not  associate
with MR-proANP. The unknown mechanism(s) related to the pronounced
association  with  NT-proBNP  rather  than  BNP  are  specific  enough  not  to
affect circulating MR-proANP.
Rs61761991 in N-terminal proBNP associated with a dramatic decrease in
measured  NT-proBNP concentration,  with  no  effect  on  BNP.  As  the  SNP is
located in the region used as the antigen to develop antibodies for NT-
proBNP immunoassays, the simplest explanation is that NT-proBNP
antibodies have low affinity to the rarer rs61761991 allele [186]. While the
SNP is very rare elsewhere, its minor allele frequency is approximately 2% to
3%  in  Finland.  Roughly  one  out  of  twenty  Finns  are  thus  heterozygous  for
rs61761991 and may present with artefactually low NT-proBNP
concentrations, possibly causing mistaken rule-out of suspected heart failure.
The unluckiest one out of thousand Finnish individuals are rare rs61761991
homozygotes and will present essentially zero values for NT-proBNP assays.
The  potential  effect  on  diagnosis  of  HF  would  be  eliminated  by  using  C-
terminal BNP rather than NT-proBNP assays in the Finnish population.
5.4 TAKOTSUBO CARDIOMYOPATHY
A GWAS of Takotsubo cardiomyopathy in study IV did not identify genome-
wide significant loci and showed a nonreplication for loci reported by prior
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studies. The study sample was limited in size, and we estimated that we had
adequate power to detect only common, high-risk disease alleles in the
genome-wide setting. The situation was better for the targeted replication of
previously reported results, where multiple testing burden was less severe.
Scientific  progress  on  Takotsubo  cardiomyopathy,  the  curious  form  of
transient heart failure, has been severely hampered by small patient cohorts.
This is the result of TTC being a rare, late-onset disease, which has only quite
recently been described. In fact, a large part of the modern literature on TTC
consists of case studies describing single patients rather than cohorts of any
size.  Compared  to  the  status  quo,  the  cohort  investigated  in  study  IV  is  an
improvement.  The  study  sample  was,  however,  far  from  large  enough  to
identify disease alleles with low penetrances and effect sizes typical of
complex diseases, where odds ratios are with few exceptions below 1.5.
Given that data on TTC is extremely limited, scientists should extract as
much utility from the data at hand as possible. In the meta-analysis of the
recently  published  GWAS  of  TTC,  and  the  results  from  study  IV,  one  locus
was nominally statistically significant [223]. Although this SNP in the
glutamate metabotropic receptor 7 gene GRM7 is not statistically significant
after accounting for the number of variants in the meta-analysis, it is the top
result in the combined analysis of the two most extensive genetic studies of
TTC to date. As GRM7 is related to fear response and stressful situations are
known to be among the triggers of TTC, GRM7 may be the best candidate for
molecular  studies  in  TTC,  regardless  of  the  SNP association  failing  to  meet
strict statistical significance [249,250].
5.5 LIMITATIONS AND FUTURE PROSPECTS
The study of human disease is ultimately aimed at producing effective
preventive strategies or treatments. In this respect, the utility of the results
from  studies  I  to  III  is  limited  by  the  inability  to  conclusively  attribute  the
observed trait associations to specific genetic variants and genes. Despite our
attempts at deciphering these associations, success was limited and leaves
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much to be desired. The findings do not unambiguously point to specific
biological mechanisms which could be targeted in hypertension or
myocardial infarction to, ultimately, ease the population burden of heart
failure. This limitation is shared by most results from GWA studies, with rare
exceptions,  such  as  the  NT-proBNP  SNP  rs61761991,  where  the
interpretation of the results is easier mostly by coincidence. Addressing this
limitation systematically to reap the full benefits from GWA studies will
probably require the development of entirely novel analytical or
experimental approaches.
The GWA analysis of Takotsubo cardiomyopathy in study IV was limited
by its small sample size. The study sample was not statistically well powered
to identify genome-wide significant associations to genetic variants with
modest or small effect sizes. Future studies of TTC will require substantially
larger samples to address genetic variation typical of complex disease.
The results of GWA studies are often quantified in terms of the fraction of
heritability explained by all known loci or the newly identified loci alone.
These estimates can then be used to assess whether new studies of the same
traits are justified. The samples investigated in this thesis are not large
enough  to  produce  such  estimates  with  meaningful  precision  for  the  loci
identified in the present studies. However, the fraction can be expected to be
small,  as  the  loci  are  few  and  their  effect  sizes  are  modest.  In  the  future,
much larger GWA studies will almost certainly identify new loci. Although
ever  larger  GWA  studies  have  been  criticized,  and  valid  questions  of  their
potential value have been raised, they represent a rare simple path forward
among the complexities of biology [251]. Even if their value cannot be
guaranteed, future GWA studies of millions of people will be a reasonable use
of scientific resources.
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6 CONCLUSIONS
In  study  I,  we  identified  rs2287696  in PRDM6 as  associated  with  blood
pressure and risk for intracranial aneurysms. Based on prior reports on the
biological function of PRDM6,  we speculated,  in the original  study,  that  the
association was related to the level of PRDM6 expression in the arterial wall.
Recently  published  data  supports  a  link  between  rs2287696  and  arterial
PRDM6 expression.
Study II, a GWAS of MI, identified a locus on chromosome 1 near DRAM2
associated with increased risk for NSTEMI with a much weaker effect for
STEMI. This result was an outlier among variants previously associated with
risk  for  coronary  artery  disease,  which  did  not  show  marked  differences
between NSTEMI and STEMI in our study sample. The NSTEMI association
is likely related to pathomechanisms other than the onset of coronary artery
disease.
The genome-wide analysis in study III associated several variants in three
loci near NPPA-NPPB, GALNT4, and PPP3CC with  the  circulating
concentration of natriuretic peptides. Variants associated with increased
circulating MR-proANP also correlated with lower blood pressure and lower
risk of hypertension. Variants associated with BNP or NT-proBNP did not
associate with blood pressure. The genetic data thus supports the role of ANP
in  blood  pressure  regulation  in  the  general  population  but  does  not  offer
similar support for BNP.
Rs61761991 in N-terminal proBNP associated with a dramatic decrease in
measured NT-proBNP concentration, with no effect on BNP. The association
is likely caused by a reduced affinity of the NT-proBNP assay antibody to the
rarer rs61761991 allele. Roughly one out of twenty Finns are heterozygous for
rs61761991, possibly causing mistaken rule out of suspected heart failure.
This  risk  would  be  eliminated  by  using  C-terminal  BNP  rather  than  NT-
proBNP assays in the Finnish population for diagnosis of HF.
The GWA study of Takotsubo cardiomyopathy did not identify
susceptibility loci. Furthermore, previously reported associations did not
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replicate in our study sample. Taken together with the estimates of statistical
power for our study sample, these results indicate that there are no common
alleles  conferring  moderate  to  high  risk  for  TTC  in  the  Finnish  population.
The results also mostly refute the associations published in previous studies.
If genetic predisposition to TTC does exist, it is likely due to variants with low
penetrance, low allele frequency, or both.
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